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1. 
INTRODUCTION 
 
Hepatitis C virus (HCV), a single stranded positive RNA virus of the Flaviviridae 
family, chronically infects about 3% of the world’s population and often results in 
cirrhosis or liver cancer, thus representing a considerable public-health problem.!
(1-3) According to the WHO, two-thirds of liver transplants are linked to HCV 
infection.(3) Acute infections and less-advanced stages of chronic disease are 
usually clinically silent; therefore the majority of patients are unaware of their 
infection.(2) This results that HCV is frequently diagnosed in a late stage when 
therapeutic options and probability of cure are already limited. Unfortunately, 
almost 75% of HCV deaths occurred among adults between the ages of 45 and 64 
that exceeds the mortality rate of HIV.(2, 4)  
 
Although the HCV was cloned in 1989, the lack of adequate in vitro models has 
hampered our understanding of the disease pathogenesis and development of 
new therapeutic approaches. The HCV research gains momentum in 2005 when 
the first cell culture model supporting complete HCV replication was 
established.(5, 6) The replicon was a HCV genotype 2a clone isolated from 
Japanese patient with fulminant hepatitis (clone JFH-1).(5, 6) At the same time, 
progress in whole-genome sequencing technologies has opened a new era in 
genomics.(7) This represented a major breakthrough in the HCV field and enabled 
a broad range of fundamental and applied studies that lead to the development of 
new HCV disease models.  
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1.1. HCV VIROLOGY AND LIFE CYCLE 
The HCV is a small (55–65 nm in size), enveloped, single-stranded, positive 
sense RNA virus.(8) There are at least 6 HCV genotypes with numerous subtypes. 
HCV genome contains 5’ and 3’ UTRs (Untranslated Regions) including control 
elements required for translation and replication.(8) The HCV 5′ UTR is the most 
conserved region of the genome; it is not capped and forms a complex secondary 
RNA structure, the Internal Ribosome Entry Site (IRES) that mediates direct 
binding of ribosomal subunits and cellular factors and subsequent translation. The 
HCV 3′ UTR is relatively short, less structured and contains a poly-uridyl tract that 
varies in length. The HCV ORF (Open Reading Frame) encodes a single 
polyprotein (3,010-3,011 amino acids), which is processed into 11 proteins; 3 
structural (capsid protein C, E1, E2), a small protein p7 and 6 non-structural (NS2, 
NS3, NS4A, NS4B, NS5A and NS5B) proteins.(8) The structural organization of 
HCV genome is schematically illustrated in Figure 1.  
Figure 1. HCV viral particle structure (top), genome organization (middle) and polyprotein 
processing (bottom) 
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The complete life cycle of HCV happens in the cytoplasm of the host cell.(8) The 
binding of HCV into the host cell begins with receptor-mediated endocytosis. 
Several cell surface molecules have been proposed to mediate HCV binding and 
internalization (such as CD81, scavenger receptor B type I, SR-BI, low-density 
lipoprotein receptor, LDL-R, dendritic cell-specific intercellular adhesion molecule-
3-grabbing nonintegrin, DC-SIGN).(8) After attachment, the nucleocapsid is 
released into the cell cytoplasm as a result of a fusion process between viral and 
cellular membranes. When the virus is uncoated, it releases its positive-strand 
genomic RNA in the host’s cytoplasm, where it serves as a messenger RNA for 
the synthesis of HCV polyprotein. The polyprotein is targeted to the endoplasmatic 
reticulum (ER), where is processed via host and viral proteases. The replication 
complex is assembled at the rearranged ER membrane (membranous web), 
where it directs the synthesis of intermediate negative-strand RNA, which is 
subsequently used as a template for the generation of positive-strand 
RNAs. Importantly, the HCV RNA polymerase has no proofreading, which results 
in a creation of numerous quasispecies variants. The new positive-sense HCV 
RNA is encapsidated with the structural proteins in the nucleocapsid, which is 
presumably enveloped by 
budding into the lumen of 
the ER. Finally, infectious 
virions are transported 
through the Golgi 
compartment to the plasma 
membrane and released to 
infect new cells. The HCV 
turnover rate can be quite 
high with replication ranging 
between 1010 to 1012 virions 
per day.(8) 
 
 
Figure 2. Hypothetical HCV 
life cycle. 
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Throughout its life cycle, HCV interacts with and hijacks variety of host-cell 
factors to enhance its own replication.(9) Previous gene-expression analysis on 
acutely HCV infected hepatoma cell lines have identified ≈1800 genes differentially 
expressed upon HCV infection, and many of these genes were subsequently 
reported to control different stages of HCV replication.(9, 10) Examples include 
HS, CLDN1, EGFR and NPC1L1 gene products, necessary for efficient virus entry, 
liver specific microRNA miR122 crucial for HCV translation, PI4A and CypA in 
formation of replication complex, or apoB, apoE and DGAT1 involved in assembly 
and release of viral particles.(2, 8, 9)  
 
 
1.2. NATURAL HISTORY OF HCV INFECTION 
Upon infection, a large proportion of HCV-infected persons, ranging from 65%-
85%, develop chronic HCV infection, and are at risk for advanced liver fibrosis, 
HCV-related extrahepatic complications, cirrhosis and HCC.(1, 2) An estimated 
10%-15% of HCV-infected persons will advance to cirrhosis within the first 20 
years.(1, 2)  
 
 
Figure 3. Natural history of HCV infection 
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1.2.1. IMMUNE RESPONSE TO HCV INFECTION 
The mechanism by which HCV causes chronic infection in the majority of 
infected persons remains unclear. It is likely that HCV activates different 
mechanisms to evade host defences. Complexity of HCV replication provides 
partial explanation; it includes replication within enclosed structures (membranous 
web) that provide protection from the host's antiviral defenses; genetic diversity 
created by inaccurate replication that yields mutants resistant to the cell's antiviral 
strategies; and association of the virion with protective lipoproteins.(2, 9)  
 
1.2.1.1. Innate immune response 
Most literature has focused on the role of interference with endogenous 
interferon (IFN) system and the mechanism of disruption of the host cell ability to 
detect the virus and to respond to interferon. The recognition of RNA viral infection 
and subsequent activation of human antiviral defense mechanisms are 
accomplished primarily through signaling pathways leading to the production of 
type I interferons (IFN-α and -β).(11) These pathways are triggered by conserved 
viral pathogen associated molecular patterns (PAMPs) such as double-stranded 
RNA (dsRNA) and unmethylated CpG motifs (cytosine-guanine).(11) PAMPs are 
recognized by host cells through pathogen recognition receptor (PRR) proteins 
(such as Toll-like receptors, TLR, retinoic acid inducible gene-I (RIG-I), and 
melanoma differentiation associated gene 5), which play a major role in alerting 
cells that HCV is present and in activating antiviral pathways and genes.(11-13) In 
the settings of HCV infection, TLR-3 and RIG-I recognize dsRNA, and in turn 
function to activate transcription factors for host cell antiviral genes such as 
interferon regulatory factor-3 (IRF-3) and nuclear factor-κB (NF-κB).(14, 15) IRF-3 
and NF-κB are localized to the nucleus where they promote expression of type I 
interferons. In turn, IFNs are secreted by viral-infected cells, bind to cell surface 
receptors of both the infected and adjacent uninfected cells, and activate 
transcription of hundreds of interferon-stimulated genes (ISGs), which ultimately 
function to limit viral replication by disrupting RNA transcription and translation.(16) 
Importantly, only a small percentage of these genes have been studied regarding 
their antiviral effects in cells. However, IFN-responses in the liver do not correlate 
with the outcome of infection, even though HCV replicons are highly sensitive to 
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type I IFNs in vitro. Furthermore, HCV is able to specifically inhibit these pathways 
at multiple points and to downregulate the expression or to inhibit functions of 
antiviral genes.(9, 15, 17)  
 
 
Figure 4. Activation/inhibition of interferon system in HCV infected hepatocytes 
 
The HCV NS3-4A serine protease may block the phosphorylation and effector 
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suppress Jak (Janus kinase) – STAT (Signal Transducer and Activator of 
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functions of different ISGs.(9, 20)  
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1.2.1.2. Adaptive immune response  
Unlike acute resolving infection that is characterized by early and vigorous 
expansion of CD4+ and CD8+ T-lymphocytes, chronic infection is associated with 
delayed and weak adaptive responses, poor memory induction and deficiency of 
HCV specific cytotoxic T-lymphocytes.(21) However, the explanation of these 
phenomena remains obscure.  
 
Mutations in antibody and T-cell epitopes have been shown for both HCV-
infected humans and chimpanzees. In contrast to T-cell responses raised to other 
pathogens, HCV-specific T-cells are less differentiated and have impaired effector 
functions.(9) Finally, despite early and high viremia, HCV-specific T cells are not 
detectable in the liver within 1 month of experimental infection of chimpanzees, 
which might indicate impaired trafficking to the site of infection.(21)  
 
Given the critical role of dendritic cells (DC) in priming T cell responses, both 
DC in vitro models and DCs from chronically infected patients have been 
extensively studied, with the idea that HCV-mediated inhibition of antigen-
presenting functions could result in inefficient antiviral T-cell responses.(22-24) 
Conflicting evidence resulted from these studies; nevertheless, the ones that 
revealed a general subversion of both T-cells and DCs functions faced a problem 
that chronically infected individuals are not globally immunodeficient and have a 
relatively high level of endogenous IFNs.(22-24) Therefore, the hypothesis of 
selective impairment of local adaptive (and innate) immune responses at the site 
of the infection is favorable. Humoral immune responses appear late during 
infection or not at all, and they do not protect against re-infection. 
 
1.2.2. INFLAMMATORY RESPONSE TO HCV INFECTION 
Chronic inflammation is the major contributor of disease and is the basis of 
HCV pathogenesis.(20) However, the molecular mechanism(s) by which HCV 
confers hepatic inflammation are not defined. During chronic infection, a sustained 
production of chemokines drives persistent low-grade inflammation in the absence 
of immunocompetent Th1 response. In addition, HCV antagonizes the chemokine 
response to perturb infiltration of T-cell effector cells, thus allowing the constant 
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generation of virus particles. Meanwhile, continuous infiltration of the liver by a 
nonspecific inflammatory load causes collateral tissue damage and failure to 
eliminate the virus.(9, 20, 25)  
 
To assess hepatic gene expression patterns and host response processes 
associated with liver disease in chronic HCV infection, a systems biology analysis 
of the host response to HCV infection that included high-throughput transcriptional 
profiling of human liver coupled with in vitro modeling of the HCV/host interface 
was conducted.(26, 27) This analysis identified a broad changes in inflammatory 
networks linked with fibrosis and severity of liver disease, as presented in Figure 5.  
 
 
Figure 5. Hierarchical clustering of differentially expressed cytokine and chemokine 
genes in HCV infected livers identified major gene expression patterns that associated 
with liver disease. 
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Intrahepatic interleukin-1β (IL-1β) production was recently suggested as a 
central feature of liver inflammation during HCV infection and it was shown that 
Kupffer cells are the primary cellular source of hepatic IL-1β.(26, 27) IL-1β is 
considered as the key mediator of inflammatory response, and it is involved in a 
variety of cellular activities, including cell proliferation, growth, differentiation and 
apoptosis.(28) IL-1β activity is tightly controlled and requires two signals; “signal 
one” for production of IL-1β mRNA through NF-κB activation; “signal two”, the 
conversion of the inactive pro-IL-1β precursor, to the active cytokine through 
inflammasome signaling.(29) The mechanism of inflammasome activation in 
Kupffer cells includes activation of MyD88-mediated TLR7 signaling to induce IL-
1β mRNA expression and a potassium efflux that activates the NLRP3 
inflammasome for IL-1β processing and secretion.(26) These processes appear to 
drive the liver inflammation, and are closely correlated with liver fibrogenesis and 
oncogenesis.  
 
Finally, chronic ”low-level inflammation” is strongly interconnected with two 
other hallmarks of HCV infection, the immune tolerance and modulation of host 
immune responses that results in the virus eradication failure.(20, 25) 
 
 
Figure 6. Proposed model of chronic hepatitis C pathogenesis 
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Mechanisms proposed to account for the inherent tolerogenicity of the liver 
have not yet been validated convincingly; they may be due to a combination of 
several biological properties that distinguish the liver from other parenchymal 
organs (see below).  Although it was originally thought that HCV only infects 
hepatocytes and causes only inflammation of the liver, today there are 
accumulating evidences that HCV can enter and/or replicate in a variety of cells 
(B-cells, T-cells, monocytes, glia cells) and cause a variety of extrahepatic 
disorders (e.g. lymphoproliferative diseases).(30-40)  
 
There is growing evidence that liver non-parenchymal cells, specifically liver 
sinusoidal endothelial cells (LSEC) and Kupffer cells (KC), may play key roles in 
regulating immune responses and facilitating tolerance induction.(41-43) 
Surprisingly, the biology of HCV, specifically regarding non-parenchymal liver 
cells, has been largely neglected in currently predominant molecular approach. Of 
note, it is likely that LSEC and KC play distinct roles in providing tolerant 
environment within the liver that favors HCV persistence and chronic inflammation. 
 
 
1.3. THE ROLE OF THE LIVER NON-PARENCHYMAL CELLS 
IN HCV INFECTION 
 
The liver is thought to be responsible for up to 500 separate functions, which 
reflects in its unique position with regard to the blood circulation and unique 
immuneregulatory properties.(44) The hepatic vascular bed is dually supplied; it 
receives venous blood from almost the entire gastrointestinal tract via the portal 
vein and from the systemic circulation via the hepatic artery.(44) These drain into 
the hepatic sinusoids, thus generating a mixed arterial-venous perfusion of the 
liver.(44) The sinusoids are lined with fenestrated endothelial cells (LSEC) and 
luminal Kupffer cells (KC).(44) Between LSEC and liver parenchyma lies the space 
of Disse, which contains hepatic stellate cells (HSC) and liver resident dendritic 
cells (DC).(44) In addition, the liver is enriched in natural killer (NK) cells and 
natural killer T (NKT) cells, which have traditionally been considered as key 
cellular components of the innate immune system.(44) (Table 1., Figure 1.)  
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Figure 7. Illustration of liver sinusoids  
 
Due to the distinctive microcirculation, liver is constantly exposed to the 
nutrients and endotoxins derived from the gut. While nutrients have to be extracted 
and metabolized, blood toxic waste products, endotoxins and bacterial degradation 
products have to be eliminated without provoking immune responses. This implies 
an existence of liver-specific, immuneregulatory mechanisms that lead to induction 
of tolerance.  
 
LSEC are a morphologically distinct population of cells (due to the open 
fenestrations without a basement membrane) that form the lining of liver 
sinusoids.(44-46) Due to their position, LSEC are the first cells in contact with 
blood flow and serve to compartmentalize the vascular sinusoidal channels from 
the hepatic parenchyma.(44-46) However, LSEC are not simply barrier cells that 
restrict the access of bloodborne compounds to the liver parenchyma. LSEC have 
complex roles, including clearance of endotoxin, bacteria and other compounds, 
the regulation of inflammation, leukocyte recruitment and host immune responses 
to pathogens.(47, 48) Due to their extraordinary scavenger activity, expression of 
pattern recognition receptors (e.g. TLR3 and TLR7) and release of 
proinflammatory mediators (e.g. IL-1β, TNFα), LSEC do not depend on other 
immune cells in the initiation of inflammatory reactions.(49-51) 
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
1 According to ref. (44) 
Table 1. Sinusoidal cell populations1 
Hepatic cell population % of   
volume 
% of 
cells 
Kupffer cells 2.1 15 
Liver sinusoidal endothelial cells 2.8 19 
Stellate cells 1.4 5-8 
Liver associated lymphocytes  nd nd 
Hepatocytes 78 60 
Dendritic cells nd nd  Hepatocyte 
Kupffer 
cell 
Stellate 
cell 
sinusoidal  
endothelial  
cell 
Bile  
ductule 
Hepatic 
arteriole 
Portal venule 
space of  
Disse 
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Liver non-parenchymal cells (KC and LSEC) are known to play a pivotal role in 
blood-borne virus clearance, yet recently, using modern techniques to repeat the 
vital stain clearance studies of early 20th century, the concept of sinusoidal 
scavenging has been amended.(52) These studies showed that LSEC take up and 
destroy the majority of blood-borne viruses, processing so quickly (minutes) and 
extensively (>90%) in ways specific to each virus.(53) However, the mechanism of 
impairment of LSEC clearance capacity during HCV infection remained 
unanswered. 
 
Using a duck model of HBV infection, it was shown that LSEC rather than 
hepatocytes took up HBV and that infected hepatocytes were often observed in 
nearness of LSEC, suggesting the model of primary uptake into LSEC as a 
general mechanism by which blood borne agents are targeted to the liver.(52) 
There are growing evidences that this model applies for HCV infection also. It was 
found that HCV E1 and E2 bind L-SIGN (C-type lectin similar to DC-SIGN on 
dendritic cells), which further direct HCV particles in early lysosomal 
compartments.(54-57) These data lead us to the conclusion that rather than 
having the infection of LSECs, the bounded and internalized HCV escape host 
degradation mechanisms resulting in retained infectivity for an extended period of 
time, thus representing an efficient infectious reservoir for the underlying 
hepatocytes. 
 
LSEC have been recognized as efficient antigen-presenting cells (APC).(51) In 
contrast to other APC, they induce tolerance rather than activation of immune 
response.(51, 58, 59) This is of particular relevance in the setting of HCV infection, 
where the lack of an effective immune response is implicated in the development 
of persistent infection and the immunological characteristics of chronic hepatitis. It 
is presumed that liver APCs can exist in a state of active tolerance and contribute 
to the tolerogenic liver environment by the continuous secretion of 
immunosuppressive cytokines, e.g. IL-10 and TGF-β.(60) The immune ignorance 
model assumes that after internalization, viral particles might be processed and 
presented to naive T cells. Interaction of naive T cells with antigen-presenting 
LSECs results in differentiation of T cells into regulatory T cells and impaired 
cytotoxic T lymphocytes that are unable to produce IL-2 or interferon-γ or to exhibit 
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cytotoxicity to infected cells and that undergo apoptosis.(60) This raises the 
question of whether the tolerogenic properties of the liver APCs contribute to the 
persistence of HCV.  
 
 
Figure 8. Hypothetical tolerogenic properties of liver non-parenchymal cells 
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1.4. SYSTEM BIOLOGY APPROACHES TO HCV INFECTION 
 
Previously published gene expression analyses (mostly performed using 
microarray technology) have revealed new disease specific changes in gene 
expression, identified potential biomarkers of HCV infection and suggested a new 
mechanism of host cell-virus interaction that results in viral particle assembly, 
secretion and infectivity.(10, 61-64) However, the strategies by which HCV evades 
the surveillance of the host immune system and hijacks host cellular machinery for 
its own replication are not completely understood.  
 
According to widely accepted model, binding/internalization of HCV particle 
results in virus recognition, activation of host signaling pathways that finally lead to 
activation/inhibition of transcriptional regulators resulting in the modulation of gene 
expression.  
 
Figure 9. Model of HCV-innate immune response  (detected by gene expression studies) 
 
As previously described, the innate immune response relies on recognition of 
evolutionarily conserved structures on pathogens, termed pathogen-associated 
molecular patterns (PAMPs), through pattern recognition receptors (PRRs).(11) 
HCV infection  
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Upon PAMP recognition, PRRs signal to the host the presence of infection and 
trigger proinflammatory and antimicrobial responses by activating a multitude of 
intracellular signaling pathways, including adaptor molecules, kinases, and 
transcription factors.(11) PRR-induced signal transduction pathways ultimately 
result in the activation of gene expression and synthesis of a broad range of 
molecules, including cytokines, chemokines, cell adhesion molecules, which 
together orchestrate the early host response to infection and at the same time 
represent an important link to the adaptive immune response.(11-13) The outcome 
of virus-mediated PRR activation can range from an antiviral response that 
efficiently clears the infection to the establishment of a cellular environment that 
favors viral replication and spread.(9, 11-13, 15, 16, 23) 
 
Next generation RNA sequencing technologies (RNAseq) have opened the 
door to more accurate gene expression studies in HCV infected clinical 
biospecimens and cultured cells.(7, 65) This technology has clear advantages over 
previous methods (e.g. microarray) and has revolutionized the manner in which 
transcriptomes are analyzed; it is not limited to detecting transcripts that 
correspond to existing genomic sequences; it can reveal the precise location of 
transcription boundaries; it has very low background signal; it does not have upper 
limit of quantification and has been shown to be highly accurate for quantifying 
expression levels, so the results show a high level of reproducibility.(7, 65) 
 
Using a similar approach, we have described the first report of RNA 
sequencing analysis of 5' capped RNAs isolated from acutely HCV infected Huh 
7.5 cells that have identified many new annotated and unannotated differentially 
expressed genes during acute HCV infection that were not identified in prior gene 
array analysis.(10) Among them, follow up siRNA studies of two newly identified, 
highly upregulated genes, fucosyltransferase 1 (FUT1) and kelch domain 
containing 7B (KLHDC7B), provided evidence that their expression during acute 
HCV infection is essential for the production of HCV RNA and infectious viral 
particles.(10) Furthermore, at least 38 cell pathways enriched post infection were 
identified; examples include MAPK signaling, adipocytokine signaling, TGFβ 
signaling, apoptosis, insulin signaling pathway, RIG-I like receptor signaling, 
! 16 
extracellular matrix (EMC)-receptor pathway, NOD-like receptor signaling and 
Notch signaling.(10)  
 
A pilot study was performed to determine the drivers of inflammation in HCV 
infected liver; RNA-seq analysis of models of hepatocytes (Huh7 cells), Kupffer 
cells (THP1) and mild (fibrosis) and severe (cirrhosis) HCV+ liver 
biospeciments.(26, 27) In chronic hepatitis C liver >300 genes related to 
inflammation, chemotaxis and leukocyte activation were markedly increased 
compared to controls. Unlike RNA-seq analysis of macrophages that 
demonstrated a broad increase in IL-1β and NF-κB-responsive proinflammatory 
cytokines and chemokines, HCV did not induce a marked increase in such 
inflammatory signals in Huh7.5 cells.(10, 26, 27) Analysis of genes within these 
pathways showed increased IL-1β levels with increasing severity of liver disease 
and marked overlap in upregulated expression in macrophages exposed to HCV 
and liver specimens.(26, 27)  
 
Almost all of the HCV related gene expression studies were performed in cell 
cultures of hepatoma cell lines or clinical liver biospecimens. Heterogeneous 
cellular composition of liver tissue (constituted by hepatocytes, Kupffer cells, 
stellate cells, extracellular matrix and infiltrated cells), and the obvious resulting 
complexity of liver transcriptome, doesn’t provide insight into pathophysiological 
role of LSEC during acute or chronic HCV infection. To date, no gene expression 
study on hepatic sinusoidal endothelial cells has been published and a way of 
identifying endothelial specific pathways in HCV infection is needed to improve our 
understanding of HCV pathophysiology.   
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2. 
HYPOTHESIS 
 
HCV infection reprograms cellular gene expression of human liver sinusoidal 
endothelial cells that is implicated in the modulation of the inflammatory 
responses. 
 
3. 
AIMS AND PURPOSE OF THE RESEARCH 
 
General Aim:  
• To determine the whole Pol II transcriptome associated with immune 
response in LSECs triggered by HCV, and apply the data set toward 
understanding the molecular processes of the inflammatory response 
against HCV. 
 
Specific Aims:  
• To quantify the changing expression levels of transcripts during HCV 
infection and LPS treatment 
• To define the transcriptome associated with innate and adaptive immune 
response activation after HCV infection and LPS treatment.  
• To define endothelial specific pathways enriched after HCV infection and 
LPS treatment. 
• To define host-viral interaction network in LSECs in order of better 
understanding the development of immunotolerant environment in the liver 
• To identify changes in transcriptome that might modify fibrotic processes  
• To identify new oncogene mechanism of HCV infection 
• To compare changes in cellular transcriptomes of HCV infected LSECs with 
previous gene expression studies on Huh 7.5 and THP-1 cells. 
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4. 
MATERIALS AND METHODOLOGY 
  
4.1. MATHERIALS 
 
4.1.1. LIVER SINUSOIDAL ENDOTHELIAL CELLS 
Human liver sinusoidal cells isolated from three donors were obtained from 
ScienCell Company (California, USA). These cells were isolated from human liver, 
cryopreserved immediately after purification and delivered frozen. LSEC were 
characterized by immunofluorescent method with antibodies to vWF/Factor VIII 
and CD31 (P-CAM), and were negative for HIV-1, HBV, HCV, mycoplasma, 
bacteria, yeast and fungi.  
 
Primary cultures were established in fibronectincoated flask/plates (2µg/cm2) 
and cultured in endothelial cell selective media (ECM) (ScienCell, California, USA) 
at 37˚C in 5% CO2.  ECM consists of basal medium, 5% fetal bovine serum, 
endothelial cell growth supplement and penicillin/streptomycin solution. The 
medium was changed every three days until the culture was approximately 70% 
confluent. After that, medium was changed every day. Cells were subcultured 
when they were >90% confluent. For subculture, cells were harvested using the 
tryspin/trypsin neutralization solution, and reseeded in new fibronectin coated 
plates (5,000 cells/cm2). All the experiments were performed between 2nd – 4th 
passages. All the experiments were done in triplicates and in three time points (8, 
24 and 48 hours post HCV or LPS exposure; see bellow).  
 
4.1.2. THP-1 MONOCYTE CELL LINE 
THP-1 cells were purchased from ATCC and grown in complete RPMI-1640 
medium containing 10% fetal bovine serum, antibiotics, L-glutamine, pyruvate, and 
non-essential amino acid. THP-1 cells were differentiated by treatment with 20–
40nM of PMA overnight at 37°C.  
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4.1.3. HEPATOMA (Huh7.5) CELL LINE 
The human hepatoma cell line, Huh 7.5, was maintained in Dulbecco's 
modified Eagle's medium (DMEM) (Invitrogen) supplemented with 100 U/ml of 
penicillin, 100 µg/ml of streptomycin, nonessential amino acids, and 10% fetal 
bovine serum (FBS) (Invitrogen) at 37˚C in 5% CO2. 
 
4.1.4. PRODUCTION OF INFECTIOUS HCV JFH-1 VIRUS 
For infection studies, original HCV-JFH1 clone was used. Briefly, HCV-JFH-1 
was transfected into Huh 7.5 cells, and the culture was maintained and sub-
cultured every three days. Cell supernatants, containing infectious viral particles, 
were collected, concentrated and titrated to determine focus forming units (ffu)/ml 
using immunofluorescence assays with anti-NS5A Huh7 cell-based FFU assay. 
 
4.1.5. HCV INFECTION STUDIES 
LSEC were seeded at 50,000/well in 6-well plates (9.6cm2 per well). After 48 
hours of culture, the cells were infected with HCV at MOI of 2.5.  The inoculums 
were incubated with cells for two hours at 37°C and then extensively washed with 
PBS and supplemented with fresh complete ECM. The cells were then 
continuously cultured to 8, 24, and 48 hours. Controls were MOCK infected 
(conditioned media) cells grown under identical conditions for the same time. 
These time points were selected based on previous microarray studies showing 
maximal changes in differential gene expression after 48 of acute JFH1 HCV 
infection. The 8-hour time point was chosen as an interval when few gene 
expression differences would be observed between HCV and mock-infected cells. 
 
4.1.6. LIPOPOLYSACCHARIDE (LPS) AND CONTROL TESTING 
Ultra-pure LPS from E.coli (a potent activator of inflammatory responses) was 
purchased (Invivogen, USA) and used as control. MOCK or negative control is 
conditioned media without the virus or LPS.  
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4.2. METHODS 
 
4.2.1. RNA ISOLATION AND cDNA LIBRARY CONSTRUCTION 
Total RNA from LSEC, THP1 and Huh 7.5 cells after acute HCV exposure was 
purified using Trizol (Invitrogen, USA), as described previously.(10, 64) RNA 
quality was assessed using a BioAnalyzer RNA 6000 Nano Chip (Aglient, USA) 
and only RNA specimens yielding a RNA integrity number (RIN) of ≥9.0 were 
used. The quantity of all RNA samples was measured by NanoDrop analysis. 
Illumina TruSeq RNA Sample Preparation Kit v2 with Oligo(dT) RNA selection was 
used for poly(A) RNAs selection and cDNA libraries construction.2(10, 64) Poly(A) 
RNA were purified from 1µg of total RNA, and 100ng of cDNA library prep  were 
used for RNA-seq. 
  
4.2.2. NEXT-GENERATION RNA SEQUENCING  
Single RNA-Seq reads were obtained using Illumina HiSeq 2000, 50-cycle 
protocols.3 Clusters were prepared using the Illumina cluster station according to 
the manufacturer's instructions. 
 A total of 16–26 million 50 bp reads were obtained from LSEC cell samples 
(see section 4.3.). 
 
4.2.3. REAL-TIME PCR VERIFICATION ASSAYS 
Three additional primary cell cultures (isolated from different donors) were used 
for further analysis of differentially expressed genes at each time point. Total RNA 
from infected and control cells were extracted using TRIzol. First-strand cDNA was 
synthesized using Moloney Murine Leukemia Virus reverse transcriptase 
(SuperScript III; Invitrogen) with 20ng/ml of RNA at 55°C (60 min) with random 
hexamer primers. Each qPCR reaction was carried out in a 384-well optical plate 
(Roche Applied Science) in a 10µL reaction buffer containing LightCycler 480 
Probes Master Mix (100mM Tris-HCl, 100mM KCl, 400mM of each dNTP (with !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
Available at: 
2http://supportres.illumina.com/documents/documentation/chemistry_documentation/samplepreps_t
ruseq/truseqrna/truseq-rna-sample-prep-v2-guide-15026495-f.pdf  
3 http://res.illumina.com/documents/products/datasheets/datasheet_hiseq2000.pdf!!
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dUTP instead of dTTP), 64mM MgCl2, FastStart Taq DNA Polymerase, 0.3 mM of 
each primer, 0.1mM hydrolysis probe and approximately 50ng of cDNA (done in 
triplicate)). Triplicate incubations without template were used as negative controls.  
Thermal cycling was done in a Roche LightCycler 480 System (Roche Applied 
Science). The qPCR thermo cycling was 95°C for 5 min, 45 cycles at 95°C for 10 
sec, 59°C for 30 sec and 72°C for 1 sec. The relative quantity of each RNA 
transcript was calculated with the comparative Ct (cycling threshold) method using 
the formula 2ΔCt. ΔCt represents the difference between target gene expression in 
mock-infected samples and target gene expression in HCV-infected samples. 
Reference genes (GAPDH and β-actin, ACTB) were used as controls and 
statistical significance was evaluated using the Mann-Whitney test. 
 
4.2.4. IMMUNOFLUORESCENCE ASSAYS 
For immunofluorescence assay, cells were extensively washed with PBS, fixed 
with 4% paraformaldehyde, and permeabilized with 0.2% Triton X-100. Fixed cells 
were blocked with 1% bovine serum albumin and 1% normal goat serum in PBS. 
HCV NS5A protein was detected in cells by incubation with an NS5A-specific 
monoclonal antibody and visualized with the secondary goat anti-mouse IgG 
conjugated with Alexa Fluor 594 fluorescein (Invitrogen, 1:1000 dilution). Cover 
slips were mounted onto slides with DAPI (Vector labs), and the HCV NS5A were 
visualized by fluorescence microscopy (Nikon E400). The viral titer is expressed 
as focus-forming units per milliliter of supernatant (ffu/ml), as determined by the 
average number of NS5A-positive foci detected by immunofluorescence for NS5A. 
 
4.2.5. APOPTOSIS ASSAY 
Annexin V-PE Apoptosis Kit (BD Biosciences Pharmingen, USA) allows 
fluorescent detection of Annexin V bound to apoptotic cells and quantitative 
determination by flow cytometry. The Annexin V labels phosphatidylserine sites on 
the membrane surface. The kit includes 7-Amino-actinomycin (7–AAD), a standard 
flow cytometric viability probe and is used to distinguish viable from nonviable 
cells. This combination allows the differentiation among early apoptotic cells 
(annexin V positive, 7-AAD negative), cells that are either in the end stage of 
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apoptosis, undergoing necrosis or are already dead (annexin V positive, 7-AAD 
positive), and viable cells (annexin V negative, 7-AAD negative). 
 
For apoptosis experiments, LSEC were harvested and washed in cold 
phosphate-buffered saline (PBS). Cells were resuspended in 1X annexin-binding 
buffer to ≈1×106 cells/mL. 5µL Annexin V and 5µL 7-AAD was added to each 100 
µL of cell suspension. After the 15min incubation period at room temperature, 400 
µL 1X annexin-binding buffer was added and the stained cells were analyzed by 
flow cytometry (BD FACSCanto™, BD Biosciences, USA).  
 
 
4.3. BIOINFORMATICS 
 
RNA sequencing reads were aligned to the February 2009 human reference 
sequence genome (GRCh37/hg19, using the NovoAlign read aligner.(66, 67) 
Visualization tracks were prepared for each of the samples using the USeq 
ReadCoverage application; these tracks can be viewed using the Integrated 
Genome Browser (IGB).(67)  
 
The DEseq (R/Bioconductor) application was used to identify differentially 
expressed genes. Bioinformatics analysis of the RNA-seq data includes 
adjustments for the depth of sequencing.(68, 69) DEseq application was used to 
count reads intersecting exons of each annotated gene and score them for 
differential expression in each sample. Scores were controlled for multiple testing 
and ranked by false discovery rate (FDR) and normalized ratio.(68, 69) Genes 
designated as significantly differentially expressed have an untransformed FDR of 
<0.05 (<5 false positives per 100 observations) and normalized change of ≥1.25 
fold relative to controls.  
 
DAVID4 (The Database for Annotation, Visualization and Integrated Discovery), 
BioMart Software 5 , and GeneOntology 6  were used to identify enriched !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
4 http://david.abcc.ncifcrf.gov/  
5 http://www.ensembl.org/biomart/martview/e6d8b6deca5eb84e3ea3de14f3ee17c9  
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GeneOntology terms, KEGG pathways and relationship of changed genes with 
cellular processes. Network of enriched GO terms was created using the 
Cytoscype application7. Kegg pathways maps were created using the PathVisio 
software8.  
 
 
Figure 10. DESeq results. Classification of transcripts according to gene biotype.  
 
 
 
  
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
6 http://www.geneontology.org/  
7 www.cytoscape.org/  
8 http://www.pathvisio.org/!!
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4.4. RESEARCH PLAN 
 
This study had 4 phases: 
 
1. Establishment and infection of LSEC primary cultures 
2. Isolation of total RNA, polyA selection, preparation of cDNA libraries 
for RNA-seq 
3. RNA-seq 
4. Bioinformatics 
 
Research plan is shown in Diagram below:  
RNA$seq(EXPERIMENTAL(PROTOCOL(
Human&hepa*c&sinusoidal&
endothelial&cells&infec*on&
Prepara*on&of&whole&Pol&II&
RNA&transcriptome&
Next&genera*on&RNA<seq&
(Illumina)&
&
LSEC(cells((ScienCell,*USA)*
50,000/well*in*ﬁbronec6n*coated*6;
well*plates*
&&&&
************48hr&
&
&
&
HCV$JFH1(((MOCK(((((LPS(
(moi=2.5)*****************************(10μg/mL)*
*
**********2h*********************2h*
&
&&&&&&&&Washed&3x&PBS;&
Supplemented&with&fresh&&
&&&&&complete&medium&
&
&
&
&
Con*nuously&cultured&to&8,&24&
and&48&hours&
&
Puriﬁca*on&of&total(RNA(&
(Trizol,*Invitrogen)*
&
&&&&&&&&&&1μg*
*
Illumina(TruSeq(RNA(Sample(
PreparaDon(Kit(v2(
with&Oligo(dT)&RNA&selec*on&&
&
&&&&&&&&&&&&&
RNA(quality(analysis(
(BioAnalyzer*RNA*6000*Nano*Chip,**
BioAnalyzer*DNA*1000*Chip,*Agilent)*
*
*
*
cDNA&synthesis&&&&&&&&&&&&&&cDNA&library&
MOCK&(n=9)&&&&&&&&&&&&&&&&&&&&&&&&MOCK&(n=3)&
HCV&(n=9)&&&&&&&&&&&&&&&&&&&&&&&&&&&&HCV&(n=3)&
LPS&(n=9)&&&&&&&&&&&&&&&&&&&&&&&&&&&&&HCV&(n=3)&
&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&
*************
&
&
Illumina(RNA(sequencing(
Single;end*RNA;seq*of*100ng*cDNA*
(HiSeq*2000,*50*cycles)*
&
&
BIOINFORMATICS(
NovoAlign*short*reader*aligner;*
DEseq*(R/Bioconductor);*Cuﬄinks*
Useq:*Integrated*Genome*Browser*
*
*
IdenDﬁcaDon(of(diﬀerenDally(
expressed(genes((
(FDR<0.05,&FC≥1.25x)&
*
************************DAVID;*Gene*Ontology;*
BioMart*
*
Unnanotated*************KEGG*pathways*
transcripts*****************************GO*terms*
&
&
Veriﬁca*on&assays&
! 25 
5. 
RESULTS 
 
5.1. HCV JFH-1 INFECTION OF HUMAN HEPATIC 
SINUSOIDAL ENDOTHELIAL CELLS 
 
Primary cultures of human LSECs isolated from three donors were infected 
with HCV JFH-1 for 2 hours with a relatively high MOI of 2.5 virions/cell. As 
previously reported (57), we did not find a proof of HCV replication in primary 
human LSEC cultures, as measured by anti-NS5A immunostaining 48, 72 and 96 
hours after HCV infection. Surprisingly for the cell system that doesn’t support 
HCV replication, there was no decrease of cellular HCV RNA titer measured by 
qPCR at 24 or 48 hours as compared with 8 hours post infection (98%), 
suggesting that HCV RNA is stable in LSECs, at least for the highly conserved 
target sequence in the 5'UTR region of HCV genome that was used for qPCR 
amplification. These data lead us to the conclusion that rather than having the 
infection of LSEC, the bounded and internalized HCV escape host degradation 
mechanisms resulting in retained infectivity for an extended period of time, 
possibly representing an efficient infectious reservoir for the underlying 
hepatocytes. 
 
Since it is possible that the long single strand HCV RNA molecule may 
fragment during the infection after such that the virus is no longer viable for 
infection, we designed an experiment to test if HCV retains its infectivity in LSEC. 
LSEC cell cultures were infected with HCV and cultured for 72 hours, extensively 
washed with PBS to remove the un-internalized HCV particles, trypsonised and 
co-cultured with Huh 7.5 cells. After 48 hours of cultivation, co-cultures were 
immunostained against HCV NS5A. While control Huh 7.5 cells infected with 
supernatants from HCV infected LSECs (from the first part of the experiment) did 
not show any immunofluorescence, LSEC-Huh 7.5 co-cultures were positive for 
HCV NS5A. Additional control, Huh 7.5 cells exposed to HCV particles incubated 
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in cell free medium at 37OC for 72 hours showed a few NS5A positive colonies. 
This experiment cannot exclude infection from the bound, but not internalized virus 
(although cultures were extensively washed and trypsonised). Since LSECs 
supernatant didn’t cause HCV replication in Huh7.5 cells, at least for the 6 cultures 
isolated from 2 donors that were tested, and in addition to qPCR data that showed 
HCV RNA stability, our results can suggest that HCV partly retains its infectivity in 
LSEC.   
 
 
 
 
Figure 11. Panel A. HCV NS5A immunostaining of Huh7.5 and LSEC. Panel B. Infectivity 
of HCV-JFH1 in LSEC (details in text). 
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5.2. GLOBAL TRANSCRIPTIONAL RESPONSE TO HCV 
INFECTION AND LPS STIMULATION OF LSEC 
 
The poly(A) selected RNAs from HCV infected, LPS stimulated and control 
cells were analyzed by next-generation RNA sequencing (RNA-seq) and data 
processed as described in Methods.  
 
5.2.1. LPS INDUCED TRANSCRIPTIONAL RESPONSE  
Lipopolysaccharide (LPS), a mayor structural component of the outer wall of all 
Gram-negative bacteria, has been widely used to describe the activation of host 
cell immune and inflammatory responses. Although the effects of LPS on hepatic 
metabolism and host immune response are extensively studied, the direct 
responses of human LSECs to LPS and the corresponding extent of gene 
expression changes have not been characterized using whole genome sequencing 
approach. RNA-seq showed that LPS stimulation promptly and dramatically 
changes gene expression. A total of 3949, 1912 and 1433 genes were 
differentially expressed at 8, 24 and 48 hours, respectively (fold change ≥1.25 and 
false discovery rate (FDR) >13), as presented in Figure 12.  
 
 
 
Figure 12. A Venn diagram depicting the number of genes that are differentially 
expressed at 8, 24 and 16 hours after LPS exposure is shown. 
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These data are unusual in comparison to other cell lines, in which number of 
differentially expressed genes usually gradually raises and rarely achieve similar 
number at 72 hours in comparison to only 8 hours of LPS stimulation of 
LSECs.(10, 62) Furthermore, the number of differentially expressed genes 
significantly dropped at 24 hours, and the same trend continued at 48 hours. This 
might suggest that in addition to exceptionally fast and potent activation of 
inflammatory responses, LSECs actively attenuate inflammatory response at the 
gene expression level.  
Figure 13. Time course of gene expression in LPS stimulated LSEC. Fold changes of 
selected inflammatory mediators are shown.  
  
Indeed, the fold changes of proinflammatory genes decreased significantly 
from 8 to 48 hours (IL-1β 25.9- vs. 10.5-fold increase; IL6 6.1- vs. 4.6-; TNFα 12.8- 
vs. NS; OAS2 19.2- vs. 1.8-; MX1 43.1- vs. 2.1-; 8hr vs. 48hr fold increase). These 
changes were accompanied with upregulation of several negative regulators of 
transcription that were not expressed at 8 hours (encoded by SALL2 3.2-, SATB1 
3.0-, DACH1 2.5-, GLIS3 2.3-fold increase at 48 hours) and decreased expression 
of positive regulators of transcription in comparison to 8 hours post stimulation 
(FOSL1 1.6 vs. -2.1; IRF7 6.5 vs. 1.5; NOLC1 1.3 vs. -1.3; RUNX1 1.2 vs. -1.4; 
MYC 1.0 vs. -1.3).  
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Figure 14. Time course of gene expression in LPS stimulated LSEC. Fold changes of 
positive (upper panel) and negative (bottom panel) of transcription in LPS stimulated 
cells are shown. 
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5.2.2. HCV INDUCED TRANSCRIPTIONAL RESPONSE 
 
HCV infected LSECs showed entirely different pattern of gene expression. The 
total number of DEGs decreased significantly from 8 hours (754) to 24 hours (245) 
and then significantly rose again at 48 hours (2543) (Figure 14). The proportion of 
genes in common was much lower at 48 hours than at 8 or 24 hours, and the most 
of the gene changes were restricted to 8, 24, or 48 hours rather than persisting 
across time points. Additionally, in contrast to LPS stimulated LSECs, the majority 
of DEGs were observed at 48 hours after HCV infection. Presented kinetics of 
gene expression might suggest early vs. late response to HCV infection. This 
might be a reflection of HCV potential for chronicity, where by causing minimal 
impact upon entry into cells, HCV delays cellular changes in order to prevent the 
activation of immune response. Similar results were obtained from in vitro studies 
on hepatocyte models as in the in vivo studies of HCV infection in chimpanzees, 
where virus efficiently replicates in the absence of gene expression changes and 
activation of the immune response.  Indeed, majority of changes in mRNAs related 
to immune response were restricted to 48 hours post HCV infection in our 
analysis.   
 
 
Figure 14. A Venn diagram depicting the number of genes that are differentially 
expressed at 8, 24 and 16 hours after HCV exposure is shown. 
406 282 2543 
85 
94 
49 17 
48hr 
2959 genes 
8hr 
754 genes 
24hr 
245 genes 
! 31 
Approximately 57%, 51% and 48% of DEGs were downregulated at 8, 24 and 
48 hours after HCV infection, respectively. Downregulation of genes is relatively 
uncommon event in gene expression analysis. This might suggest a different 
pattern of gene reprograming as a special characteristic of LSECs, where cells 
shut down their normal functions that can benefit or limit virus infectivity. Since, 
HCV does not replicate in LSECs, these changes should not correlate with HCV 
replication cycle, viral titer or presence of dsRNA, as in Huh 7.5 cells where the 
host transcriptional response corresponds closely to the levels of HCV replication, 
but rather suggest a different means of transcriptional activation. Furthermore, it 
was observed that viral attachment and entry into hepatocytes doesn't significantly 
impact host gene expression,(62) as was not the case in LSECs. Interestingly, in 
comparison to acutely infected Huh 7.5 cells, approximately 76% of changed 
transcripts were unique for HCV infected LSECs.  
 
Interestingly, 920 genes overlapped between LPS and HCV exposed cells, 
representing 31%. However, while in LPS exposed cells the proinflammatory 
genes were highly expressed, the majority of these genes were downregulated in 
HCV infected LSEC.  
 
Figure 15. A Venn diagram depicting the number of genes that are differentially 
expressed at 48 hours after HCV infection and 8 hours after LPS exposure is shown. 
Genes that were significantly differentially expressed in both LPS and HCV exposed cells 
are shown in the overlapping regions. 
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Changes in gene expression revealed a broad and complex cellular 
transcriptional reprograming in wide range of gene functional categories and many 
of these DEGs haven't been previously associated with HCV infection. Gene 
ontology (GO) analysis was used to annotate the differentially expressed genes to 
their associated biological processes. All DEGs were subjected to GO term 
enrichment analysis that revealed 435 GO terms at the thresholds of 5 genes 
within the category and conservative FDR of <0.05 (at 48 hours time point). 
Notably, many of the differentially expressed genes belong to functional categories 
related with immune and inflammatory responses (103), cell adhesion (142), 
signaling (200), cell death (145), cell cycle (149) and cell growth/proliferation (153).  
Figure 16. Gene ontology analysis of differentially expressed genes 48 hours after HCV 
infection.
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TABLE 2. The 20 most highly upregulated genes after HCV exposure. Annotated genes that were significantly increased after HCV 
exposure, relative to MOCK treated cells, are presented in the order of their fold change are indicated. 
  
Ensambl Gene ID Gene Name Gene Description FDR 
Fold 
Change 
ENSG00000138315 OIT3 oncoprotein induced transcript 3 94 19.4 
ENSG00000132514 CLEC10A C-type lectin domain family 10, member A  44 12.9 
ENSG00000134817 APLNR apelin receptor  54 10.5 
ENSG00000102575 ACP5 acid phosphatase 5, tartrate resistant  22 9.1 
ENSG00000136011 STAB2 stabilin 2  16 9.0 
ENSG00000240583 AQP1 aquaporin 1 (Colton blood group) 31 8.1 
ENSG00000176046 NUPR1 nuclear protein, transcriptional regulator, 1 96 7.2 
ENSG00000179914 ITLN1 intelectin 1 (galactofuranose binding) 28 7.0 
ENSG00000113389 NPR3 natriuretic peptide receptor C/guanylate cyclase C 13 6.8 
ENSG00000135409 AMHR2 anti-Mullerian hormone receptor, type II  17 6.6 
ENSG00000175899 A2M alpha-2-macroglobulin  70 6.2 
ENSG00000163687 DNASE1L3 deoxyribonuclease I-like 3  47 6.0 
ENSG00000182851 GPIHBP1 glycosylphosphatidylinositol anchored high density lipoprotein binding protein 1 25 5.8 
ENSG00000165810 BTNL9 butyrophilin-like 9  19 5.8 
ENSG00000130600 H19 H19, imprinted maternally expressed transcript (non-protein coding) 50 5.8 
ENSG00000104490 NCALD neurocalcin delta  21 5.7 
ENSG00000148357 HMCN2 hemicentin 2  33 5.6 
ENSG00000055955 ITIH4 inter-alpha (globulin) inhibitor H4 (plasma Kallikrein-sensitive glycoprotein)  20 5.4 
ENSG00000110876 SELPLG selectin P ligand 65 5.4 
ENSG00000137033 IL33 interleukin 33  18 5.2 
ENSG00000117643 MAN1C1 mannosidase, alpha, class 1C, member 1  28 4.9 
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TABLE 3. The 20 most highly downregulated genes after HCV exposure. Annotated genes that were significantly increased after HCV 
exposure, relative to MOCK treated cells, are presented in the order of their fold change are indicated. 
Ensambl ID Gene Name Gene Description FDR 
Fold 
Change 
ENSG00000181634 TNFSF15 tumor necrosis factor (ligand) superfamily, member 15  16 -33.0 
ENSG00000124721 DNAH8 dynein, axonemal, heavy chain 8  14 -6.4 
ENSG00000183715 OPCML opioid binding protein/cell adhesion molecule-like  14 -5.6 
ENSG00000213694 S1PR3 sphingosine-1-phosphate receptor 3  19 -3.8 
ENSG00000164251 F2RL1 coagulation factor II (thrombin) receptor-like 1 16 -3.8 
ENSG00000152377 SPOCK1 sparc/osteonectin, cwcv and kazal-like domains proteoglycan (testican) 1 14 -3.7 
ENSG00000218336 ODZ3 odz, odd Oz/ten-m homolog 3 (Drosophila)  15 -3.3 
ENSG00000105851 PIK3CG phosphoinositide-3-kinase, catalytic, gamma polypeptide  40 -3.1 
ENSG00000164176 EDIL3 EGF-like repeats and discoidin I-like domains 3  17 -3.0 
ENSG00000152402 GUCY1A2 guanylate cyclase 1, soluble, alpha 2  94 -3.0 
ENSG00000115008 IL1A interleukin 1, alpha 13 -2.9 
ENSG00000147082 CCNB3 cyclin B3  19 -2.9 
ENSG00000135480 KRT7 keratin 7  20 -2.8 
ENSG00000146147 MLIP muscular LMNA-interacting protein  24 -2.8 
ENSG00000240694 PNMA2 paraneoplastic antigen MA2  23 -2.7 
ENSG00000180440 SERTM1 serine-rich and transmembrane domain containing 1  29 -2.7 
ENSG00000106366 SERPINE1 serpin peptidase inhibitor, clade E, member 1 15 -2.7 
ENSG00000198286 CARD11 caspase recruitment domain family, member 11  18 -2.7 
ENSG00000163293 NIPAL1 NIPA-like domain containing 1  19 -2.6 
ENSG00000092969 TGFB2 transforming growth factor, beta 2  24 -2.5 
ENSG00000101670 LIPG lipase, endothelial  23 -2.5 
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5.3. REGULATION OF PATHOGEN RECOGNITION RECEPTOR 
SIGNALING PATHWAYS IN HCV INFECTED LSEC AS 
COMPARED TO LPS STIMULATED LSEC 
 
The innate immune response relies on recognition of evolutionarily conserved 
structures on pathogens, termed pathogen-associated molecular patterns 
(PAMPs), through a limited number of germ line-encoded pattern recognition 
receptors (PRRs).(11) PRRs can be divided in membrane-bound receptors (Toll-
like receptors, TLRs and C-type lectin receptors) and cytosolic PRRs (retinoid 
acid-inducible gene I (RIG-I)-like receptors (RLRs) and nucleotide-binding 
oligomerization domain (NOD)-like receptors (NLRs)).  
 
 We found constitutive expression of the wide repertoire of PRRs in LSEC, 
indicating efficient “sentinel” function. RNA-seq analysis has shown that LPS and 
HCV differentially regulates PRRs, adaptor molecules, and cascade of kinases 
that ultimately results in different biological outcomes. More than 400 DEGs in 
HCV infected LSECs were involved in the processes of intracellular signaling.  
 HCV LPS  HCV LPS 
Toll-like receptor pathway Intracellular receptors 
TLR3 ns 1.87 RIG-I -1.45 4.86 
TLR4 -1.35 -1.82 MDA5 1.37 11.08 
CD14 2.69 2.36 LGP2 1.82 3.45 
C-type lectins PK3 -1.3 1.25 
MRC1 1.94 ns NOD-like receptors 
MRC2 1.32 -1.29 NOD1 1.31 -1.29 
CLEC12A 1.39 ns NAIP 1.40 -1.43 
CLEC12B -1.60 -3.90 NLRP1 ns -1.83 
CLEC14A 1.39 -1.58 NLRP12 1.26 ns 
CLEC1A 1.52 1.68 NLRX1 1.28 -1.55 
CLEC2B -1.39 -1.9 TABLE 4. The list of differentially 
expressed PRRs in HCV and LPS exposed 
LSEC. Fold changes as compared to 
control are shown. 
CLEC4M 1.67 ns 
CLEC3B 4.05 ns 
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HCV infected LSECs downregulate intracellular sensors of dsRNA such as 
RIG-I (1.45-fold) and PK3 (1.3-fold) but upregulate MDA5 (1.4-fold) and LGP2 
(1.8-fold). Membrane bound TLR4 that might sense HCV envelope glycoproteins, 
was downregulated 1.4-fold. Since LSECs constitutively express variety of 
mannose receptors, C-type lectins (CTLs), the upregulation of several CTLs was 
not a surprise (CLEC3B 4.1-; MRC1 1.9-; CLEC1A 1.5-; CLEC14A 1.4-; MRC2 
1.3-fold increase). Interestingly, CLEC4M or L-SIGN that showed 1.7-fold increase 
binds HCV E1/E2 glycoproteins and probably has a role in intracellular HCV 
trafficking and escape from lysosome degradation.(54) This might suggest that 
HCV specifically upregulates L-SIGN receptor in order to increase uptake of the 
virus into the cells and prolong viral infectivity. 
 
Several NOD-like receptors (NLRs) transcripts were upregulated in HCV 
infected LSECs (Table 4). During infection, viruses induce PRRs-dependent 
cytosolic accumulation of inactive IL-1β precursor that “primes” the cells and upon 
a second trigger that stimulates inflammasome multiprotein complex assembly, 
caspase-1 activation and pro-IL-1β cleavage, subsequently release the mature, 
biologically active IL-1β cytokine.(29) NLRs gained interest because of their key 
function in inflammasome activation. Since we did not observe upregulation of 
IL1β mRNA level in HCV infected cells (contrary to LPS stimulated LSECs), 
suggesting that HCV by itself doesn’t induce efficient TLR or RIG-I dependent 
cytokine transcription (lack of signal 1), we can speculate that upregulation of 
NLRs and several other inflammasome components might indicate activation of 
second signal necessary for and inflammasome proteins oligomerization and 
activation of caspase-1. However, in LPS treated LSECs, where IL1β was 
significantly upregulated, NLRs were downregulated while important genes 
involved in terminating PRRs responses, such as A20 and CYLD where 
upregulated (4.4- and 1.5-fold increase, respectively). This might represent a 
negative feedback and attenuation of the inflammatory response to LPS, as we 
previously suggested. 
 
The concept of PRR-signaling involves the recruitment of one or several 
adaptor molecules that activates downstream signal transduction pathways via 
phosphorylation, ubiquitination or protein-protein interactions. In closer look to the 
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downstream transcripts of PRR-signaling pathways after HCV exposure, many 
essential genes were significantly altered. Examples include: 
 
• SARM, sterile alpha- and armadillo motif-containing protein, a negative 
regulator of TRIF-dependent TLR signaling,(70) was upregulated 1.5-fold in 
HCV infected LSECs as compared to control.  
• TRAM, TRAF1, TRAF3 and TANK, adaptor proteins of TLRs, were 
significantly downregulated after HCV infection (1.25-, 1.4-, 1.3-, 1.25-fold 
decrease, respectively).  
• Single immunoglobulin IL-1 receptor-related molecule (SIGIRR) was 
upregulated 1.5-fold in HCV infected LSECs. SIGIRR is an Ig-like 
membrane protein critical for negative regulation of TLR1, 4, 5, and 9 and 
IL-1 -mediated immune responses.(71)  
• RNF125, ring finger protein 125 (1.8-fold increase), induces ubiquitination 
and proteasomal degradation of RIG-I, MDA5 and IPS-1, which results in 
termination of IFN responses.(72)  
• ZFP36 (or TTP), zinc finger protein 36 homolog, a gene that promotes the 
rapid decay of various mRNAs, was 1.5-fold upregulated in HCV infected 
cells. TTP has been shown to promote destabilization of GM-CSF, TNFα 
and some CXC- chemokines through binding to the AU-rich RNA.(73)  
This might suggest that PRRs signaling pathway and subsequent IFN- and 
inflammatory responses are inhibited on several different levels. Since RIG-I (and 
partly TLRs) signaling pathway is critical for the activation of the type I IFN-
dependent antiviral innate immune response to HCV infection, its inhibition might 
be crucial in establishing virus-friendly environment within the liver. Importantly, 
while hepatocytes enable full HCV replication with production of non-structural 
(NS-) proteins that can block PRRs signaling, in LSEC a non-replicative HCV 
infection is sufficient to hamper RIG-I and TLR-pathways. Figure 17. shows 
enrichment of RIG-I pathway in HCV infected LSEC.   
!
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Figure 17.  Enrichment of RIG-I signaling pathway in HCV infected LSEC. 
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5.4. REGULATION OF TRANSCRIPTION DRIVES ANTI-
INFLAMMATORY RESPONSE TO HCV INFECTION 
 
Transcription factors (TFs) are regulatory proteins with function to activate or 
inhibit transcription of DNA and are considered the most important and diverse 
mechanisms of gene regulation. For example, in order to initiate the innate 
immune and further activate and shape adaptive immune responses, signaling 
pathways induced by PRRs needs to activate transcription factors, most notably 
NF-κB, AP1 and IRF3/7 due to their capacity to stimulate the production of 
proinflammatory mediators, including cytokines and IFNs. 
 
While LPS stimulated cells at 8 hours time point showed markedly upregulated 
transcriptional factors (such as ETV7 10.9-fold, CEBPD 10.6-fold, POU2F2 9.2-
fold, IRF7 7.7-fold, RELB 5.8-fold, NFКB2 4.4-fold, AP1 2.2-fold increase) crucial 
for inflammatory response, HCV infected LSECs showed decreased approximately 
20% of DEGs involved in regulation of transcription.  
 
This includes:  
• HDAC9 (histone deacetylase 9) 3.4-fold decrease, a histone 
deacatylase that alters chromosome structure and affects transcription 
factor access to DNA;  
• EGR3 (early growth response 3) -2.8-fold, a critical determinant of VEGF 
signaling and monocyte adhesion;(74)  
• IRF6 (interferon regulatory factor 6) -2.0-fold, a member of IRF family 
involved in regulation of cell cycle, differentiation, adhesion;(75)  
• ZBTB16 (zinc finger and BTB domain containing 16) -1.6-fold decrease, 
a member of Krüppel-type transcription factors involved in cell cycle 
progression.(76)  
In addition, 5% of DEGs that were increased are involved in negative regulation 
of transcription (such as MXD4 and HES1 both 1.4-fold; MDF1 and FOXP4 both 
1.3-fold increase) at 8 hours infection. The list of 25 differentially expressed TFs 
with description of their physiological role is shown in Table 5. 
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The member of Maf family, v-maf musculoaponeurotic fibrosarcoma oncogene 
homolog B (MAFB), as a basic leucine zipper transcriptional factor plays a role of 
transcriptional activator or repressor. It acts as a negative regulator of the 
expression of type I interferon genes and antagonizes anti-viral responses primary 
by blocking IRF3 and disrupting enhanceosome, a transcriptional system that 
regulates the IFN-β stimulated genes expression including the chemokines (e.g. 
CCL5 and CXCL10) suggesting a wide contribution in modulating antiviral 
response.(77, 78) RNA-seq analysis showed 4-fold increase at 48 hours HCV 
infection and 2-fold decrease at 24 hours in LPS treated cells which were 
confirmed by qPCR, as presented in Figure 18, Panel A and B.  
Figure 18. Increased expression of v-maf musculoaponeurotic fibrosarcoma oncogene 
homolog B (MAFB) in HCV exposed LSEC. Panel A. Gene expression is displayed as the 
number of sequencing reads per kilobase of gene length per million reads (RPKM) using 
the Integrated Genome Browser (IGB). The y-axis represents RPKM, and x-axis 
represents chromosome location and gene structure, orientation and chromosomal 
location. Panel B. and Panel C. show qPCR verification analysis of 9 additional HCV+/- 
and LPS +/- samples. 
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9 Gene description according to NCBI REFseq, available at http://www.ncbi.nlm.nih.gov/gene/ 
TABLE 5. The 20 differentially expressed transcriptional regulators in HCV-exposed cells 
 
Gene Name FDR Fold Change Description
9 
NUPR1 nuclear protein, transcriptional regulator, 1  96 7.2 induces the expression of the anti-inflammatory genes 
IL33 interleukin 33  18 5.2 negatively regulates  proinflammatory NF-КB dependent transcription 
HEYL hairy/enhancer-of-split related with YRPW motif-like 16 4.5 transcriptional repressors and downstream effector of Notch signaling 
MAFB v-maf musculoaponeurotic fibrosarcoma homolog B 18 3.8 negative regulator of the expression of type I interferon genes 
TXNIP thioredoxin interacting protein 70 3.6 involved in activation of the NLRP3 inflammasome  
KLF15 Kruppel-like factor 15  70 2.9 negatively regulates proinflammatory NF-КB dependent transcription 
STAT4 signal transducer and activator of transcription 4  17 2.7 transcription activator 
POU4F1 POU class 4 homeobox 1  17 2.6 regulates cell proliferation and survival, antiapoptotic role 
HIF3A hypoxia inducible factor 3, alpha subunit  17 2.5 negative regulator of hypoxia-inducible gene expression 
IGF2 insulin-like growth factor 2 (somatomedin A)  58 2.4 involved in development and growth 
SNAI2 snail homolog 2 (Drosophila)  17 2.4 transcriptional repressor , antiapoptotic activity 
CEBPD CCAAT/enhancer binding protein (C/EBP), delta  51 2.3 contributes to immunosuppression and inhibits phagocytosis 
CDKN1C cyclin-dependent kinase inhibitor 1C (p57, Kip2)  27 2.2 tumor supressor, negative regulator of cell proliferation 
HSF4 heat shock transcription factor 4  28 2.2 negative regulation of DNA binding activity 
CAMK4 calcium/calmodulin-dependent protein kinase IV  19 -2.1 regulates the activity of several transcription activators 
RUNX1 runt-related transcription factor 1 20 -2.1 cell context-dependent transactivator or repressors 
POLR3G polymerase (RNA) III polypeptide G (32kD) 15 -2.1 DNA sensing pathway involving RNA polymerase III and RIG-I 
RARB retinoic acid receptor, beta  47 -2.3 limits growth of many cell types by regulating gene expression 
MITF microphthalmia-associated transcription factor  19 -2.3 promotes cancer and chronic inflammation 
SFRP1 secreted frizzled-related protein 1  16 -2.4 regulation of Wnt pathway 
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Nuclear protein transcriptional regulator 1 (NURP1) promotes the transcription 
of stress-regulated genes and the cellular growth in a way that helps the tissue to 
neutralize diverse injuries.(79, 80) It prevents autophagy, apoptosis and cell 
death.(79, 80) NURP1 was upregulated 7.2-fold in HCV infected LSECs as 
compared to control. The upregulation of NUPR1 in acute pancreatitis was 
correlated with the ability of the defense mechanism of the pancreatic cells by 
inducing the expression of the anti-inflammatory genes.(81) 
 
Hypoxia inducible factor 3, alpha subunit (HIF3A), a member of hypoxia 
induced transcription factors family that besides O2-dependent activation pathways 
can also be induced by inflammatory stimulus, was 2.6-fold increased in HCV 
infected LSECs. In contrast to HIF1A that was upregulated after LPS stimulation; 
HIF3A does not potentiate inflammatory response, but rather negatively regulate 
hypoxia-inducible gene expression.(82)  
 
CCAAT/enhancer binding protein delta (CEBPD) transcription factor that 
inhibits macrophage-mediated phagocytosis of damaged cells was 2.3-fold 
increased in HCV infection.(83) CEBPD positively regulates PPARD, which 
showed 1.5-fold increase in HCV infected LSECs. As a member of the peroxisome 
proliferator-activated receptor (PPAR) family it attenuates the increase of 
inflammatory cytokines and acute phase proteins such as IL-1β, IL-6 or TNF-α. 
Recent studies have reported that the anti-inflammatory effects of PPARs are 
mediated by negative transcriptional control of NF-КB.(84)  
 
Several members of Ets variant (ETV-) transcriptional factors family were 
significantly downregulated in acutely infected LSECs (ETV1 1.9-; ETV3L 1.6-; 
ETV5 1.5-fold decrease). In vascular endothelium these transcription factors are 
highly induced after proinflammatory stimulation and by modulating expression of 
adhesion molecules (VCAM-1), chemokines (CCL-2) and matrix 
metalloproteinases (MPPs) contribute to the development of atherosclerosis.(85) 
In ETV1 knockdown mouse a marked reduction in the recruitment of inflammatory 
cells, as the vascular remodeling were reported in a response to systemic 
inflammation. In addition to downregulation of mentioned transcripts in HCV 
infected LSECs, several downstream targets of ETV1 were also downregulated, 
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such as CCL2 1.6; VCAM1 3.1-; MMP1 2.1-; MMP10 2.2-fold decrease 48hours 
after HCV infection. 
 
The final effect of these expression changes might be attenuation instead of 
activation of the inflammatory and innate immune responses to promote anti-
inflammatory microenvironment.  
 
 
5.5. EXPRESSION OF CYTOKINES, PRO-INFLAMMATORY 
AND ANTI-INFLAMMATORY MOLECULES IN ACUTELY 
HCV INFECTED LSEC 
 
As previously described, the ability of IFNs to confer an antiviral state depends 
on IFN mediated responses by JAK-STAT signaling pathway, resulting in broad 
expression of ISGs.(11, 21, 86) Unexpectedly, we didn’t find differentially 
expressed type I IFNs in HCV infected LSECs. Furthermore, in comparison to LPS 
stimulated LSECs that produced a variety of ISGs, HCV infected LSECs did not 
show changes in ISGs (such as OAS2, MX1, ISG15, ISG20). While LPS 
stimulated cells induced a dramatic changes in inflammatory cytokines and 
chemokines expression, in HCV infected LSEC inflammatory signals were 
attenuated.  
 
In exception of CCL14 that activates, but does not induce chemotaxis of 
monocytes (2.4-fold increase), CCL23 chemotactic for resting, but not for activated 
T-lymphocytes (3.3-fold increase), proangiogenic CXCL16 that facilitate uptake of 
various antigens (2.0-fold increase) and CXCL2 chemotactic for hematopoetic 
steam cells and neutrophils (2.4-fold increase), others members of chemokine’s 
families known to play an important role in HCV pathogenesis and previously 
suggested to be produced by sinusoidal endothelium (e.g. CXCR3, CCR5, 
CXCL10, CXCL9, CXCL11, CCL5, CCL3, CCL4), were not differentially 
expressed.  Moreover, CCL2 a chemoatractant for monocytes, and CXCL1, a 
ligand for receptor highly expressed on hepatic stellate cells (HSC) that regulates 
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HSC activation and induces fibrogenesis, were significantly downregulated, 1.6- 
and 2.1-fold decrease, respectively (Table 6) 
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Figure 19.  Panel A. The Venn 
diagram shows the number of 
differentially expressed genes that 
were unique and common to LPS 
and HCV exposed LSEC within GO: 
Immune response. Panel B. 
Hierarchical clustering analysis of 
differentially expressed genes 
common to both LPS and HCV-
exposed cells. 
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TABLE 6. List of differentially expressed cytokines and their receptors in HCV infected LSEC 
 
Ligand Receptor Function3 
CXC subfamily 
CXCL1 (-2x) 
CXCL2 (2.7x) 
IL8RB Neutrophil chemoattractant 
CXCL6 (-2.7x) 
IL8 (-2.9x) 
IL8RA Neutrophil chemoattractant 
CXCL12 (1.6x) CXCR4 (-1.4x) Lymphocytes chemoattractant; neovascularisation 
CXCL16 (2.2x) CXCR6 Lymphocytes chemoattractant 
CX3X subfamily 
CX3CL1 (-2x) CX3CR1 Promotes strong adhesion of leukocytes to activated endothelial cells 
CC subfamily 
CCL20  CCR6 (1.5x) Lymphocytes chemoattractant 
CCL2 (-1.6) CCR2 Monocytes chemoattractant 
CCL14  (2.4x) 
CCL23 (3.6x) 
CCR1, CCR3 Activates monocytes; highly chemotactic for resting T-cells and monocytes 
Hematopoietins 
IL6 IL6R (1.6x) Anti-/pro- inflammatory 
IL11 IL11RA (2.3x) Induce acute phase proteins 
LIF (2.3x),CNTF(1.3x) LIFR (1.4x) Anti-inflammatory  
CSF3 (-3.3x) CSF3R Stimulates survival, proliferation, differentiation and function of neutrophils 
LEP  LEPR (1.7x) Susceptibility to Entamoeba histolytica infections? 
IL3 IL3RA (2.6x)  Promotes endothelial cell motility and neovascularization 
PDGF family 
PDGFC (-1.3x) PDGFRB (2.4x) Modulates endothelial proliferation and angiogenesis 
HGF MET (-1.5x) “Program cell invasion” 
EGF EGFR (-2x) Cell migration, adgesion, proliferation 
VEGFC (-2x) FLT4 (-1.3) Angiogenesis, growth and survival 
CSF1 (1.4x) CSF1R Stimulates survival, proliferation, differentiation and function of macrophages 
KITLG (-1.3x) KIT (-2x) Survival, migration and tube formation of endothelium 
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TABLE 6. (continued) List of differentially expressed cytokines and their receptors in HCV infected LSEC 
 
Ligand Receptor Function10 
TNF family 
TNFSF10 (1.7x) SF10C (-1.4x) 
SF10D (-1.4x) 
Preferentially induces apoptosis in transformed and tumor cells, but does not appear to kill 
normal cells. 
TNFSF11A  SF11AS (1.9x) 
SF25 (1.6x) 
A dentritic cell survival factor and is involved in the regulation of T cell-dependent immune 
response. Involved in regulation of cell apoptosis 
TNFSF12 (-1.5x) SF12A (-1.5x) Induces apoptosis, promote proliferation and migration of endothelial cells, and thus acts as a 
regulator of angiogenesis 
TNF SF1B (1.9) Involved in the regulation of a wide spectrum of biological processes including cell proliferation, 
differentiation, apoptosis, lipid metabolism, and coagulation 
TNFSF14 (1.8x) SF14 (1.9x) Stimulate the proliferation of T cells, prevent TNFα-mediated apoptosis in primary hepatocyte 
TNFSF4 -1.9x) SF4 Involved in T-cell antigen-presenting cell interactions; This protein and its receptor are reported 
to directly mediate adhesion of activated T cells to vascular endothelial cells 
TNFSF18 (-2x) SF18  Important for interaction between T-lymphocytes and endothelial cells 
TGF-beta family 
TGFB2 (-2.4x) TGFBE1/2 Suppressive effects of interleukin-2 dependent T-cell growth 
INHBB (1.6x) ACVR Role in cell growth and proliferation 
BMP2 (1.5x) BMPR2 Regulates cell growth and differentiation 
IL1 family 
IL1A (-3.0x) IL1R1 (2.5x) A pleiotropic cytokine involved in various immune responses, inflammatory processes, and 
hematopoiesis 
IL18 IL18R1 (-1.4x) A proinflammatory cytokine  
IL33 (6.3x) IL33R Drives production of Th2-associated cytokines 
 
 !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
10 List of genes according to KEGG pathway Cytokine-cytokine receptor interaction. Fold changes are shown in brackets (symbols in red are 
upregulated, and symbols in blue are downregulated).  
Protein function is described according to NCBI REFseq, available at http://www.ncbi.nlm.nih.gov/gene/  
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Contrary to previously published upregulation of IL8 in HCV core antigen 
infected human umbilical vein endothelial cells (HUVEC),(42) we noticed a 
significant decrease of IL8 in LSECs (2.8-fold decrease). Furthermore, anti-
inflammatory cytokine IL10 and IL10 receptor IL10RA were 2-fold and 2.1- fold 
increased, respectively.  
 
Meanwhile, several highly upregulated genes were linked with anti-
inflammatory responses. 
 
Interestingly, one of the highly upregulated genes was alpha-2-macroglobulin 
(A2M, 6.4-fold increase) that was downregulated in LPS treated cells (2.4-fold 
decrease). The role of this irreversible protease inhibitor has been shown to 
predict the outcome of inflammatory conditions such as sepsis.(87, 88) The 
numerous growth factors, cytokines and hormones bind to A2M, which can inhibits 
biological effects of some of them (e.g. TGF-beta, IL1, IL6).(88) 
 
Highly upregulated member of metallophosphesterase superfamily, acid 
phosphatase 5, tartarate resistant (ACP5) showed 9.1-fold increase in HCV 
infected cells (but not in LPS stimulated), which was confirmed by qPCR analysis 
of additional samples (Figure 20, Panel A and B). ACP5 is enrolled in negative 
regulation of IL1β, IL12, TNFα production.(89) Interestingly, in humans ACP5 gene 
mutation was related with a bone dysplasia with autoimmune disorders and 
upregulation of type I interferon responses.(90) Consequently, the upregulation of 
ACP5 might be a candidate gene for impaired IFN signatures in HCV infected 
LSECs. 
 
IL1 family members are highly inflammatory cytokines, related with various 
pathologic effects, whose secretion is closely related with inflammasome 
activation.(29) Interestingly, IL1A was significantly downregulated, 3.0-fold 
decrease. However, unconventional member of IL-1 family, mainly expressed by 
cells of barrier tissues, interleukin 33 (IL33) was significantly upregulated, 5.2-fold, 
which was confirmed with qPCR analysis (Figure 21, Panel A and B).  
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IL33 induces expression of TH2 cytokines and plays an important role in TH2 
cell mobilization.(91) Importantly, TH2 cytokines (e.g. IL4, IL5 and IL13) induce 
fibrosis. IL33 also induces dendritic cells to upregulate expression of MHC class II 
molecules, and drives TH2 lymphocyte development. However it can also promote 
the resolution of inflammatory responses, inhibit TLR signaling and cause 
reduction of systemic inflammatory responses by lowering levels of IL6, TNFα, and 
CXCL2 in contrast to other IL-1 members.(92) Interestingly, non-processed IL33 
can translocate to the nucleus, where it interacts with transcription factor NFКB 
Acid phosphatase 5, tartarate resistant (ACP5) 
Chromosome 19 
!9.1x 
(FDR=22) 
5' 3' 
(11,685,475) 
48 hr HCV 
48 hr Mock 
24 hr HCV 
24 hr Mock 
8 hr HCV 
8 hr Mock 
RNA-seq 
B C
A
Figure 20. Increased expression of acid phosphatase 5, tartarate resistant (ACP5) in 
HCV exposed LSEC. Panel A. Gene expression is displayed as the number of 
sequencing reads per kilobase of gene length per million reads (RPKM) using the 
Integrated Genome Browser (IGB). The y-axis represents RPKM, and x-axis represents 
chromosome location and gene structure, orientation and chromosomal location. Panel 
B. and Panel C. show qPCR verification analysis of 9 additional HCV+/- and LPS +/- 
samples. 
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and negatively regulates NFКB dependent transcription, consequently reducing 
cytokine-mediated inflammation.(93) Recently published papers showed higher 
blood IL33 levels in patients with chronic hepatitis C and IL33 intrahepatic 
expression was strongly associated with fibrosis.(94) In addition, we identified 
LSECs as a major source of IL33, as HCV infected TPH-1 or Huh 7.5 cells did not 
significantly expressed IL33 transcript. 
 
 
 
 
Interleukin*33*(IL33)%
Chromosome%9*
!5.2x%
(FDR=18)%
3'%5'%
(6,215,805)%
48 hr HCV 
48 hr Mock 
24 hr HCV 
24 hr Mock 
8 hr HCV 
8 hr Mock 
RNA-seq 
A
B C
Figure 21. Increased expression of interleukin 33 (IL33) in HCV exposed LSEC. 
Panel A. Gene expression is displayed as the number of sequencing reads per 
kilobase of gene length per million reads (RPKM) using the Integrated Genome 
Browser (IGB). Panel B. and Panel C. show qPCR verification analysis of 9 additional 
HCV+/- and LPS +/- samples. 
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Bone morphogenetic proteins (BMPs) and BMP binding endothelial regulator 
(BMPER) are part of the TGF-β signaling pathway. Interestingly, BMP2 showed 
1.6-fold decrease, and BMP4 1.3-fold increase of mRNA and upregulation of these 
molecules were shown to lead to endothelial dysfunction in the absence of 
BMPER (BMP endothelial precursor cell-derived regulator), Figure 22.   
 
 
BMPER is a secreted glycoprotein that binds directly to BMPs and behaves as 
a BMP-antagonist.(94) RNA-seq revealed 6.3-inrease of BMPER mRNA, which 
was confirmed by qPCR analysis (Figure 19, Panel A and B). BMPER was shown 
to protect endothelial cells from TNFα-induced expression of proinflammatory 
BMP$binding$endothelial$regulator$(BMPER)$
Chromosome-7$
5' 3' 
(33,944,523) 
!4.6x 
(FDR=13) 48 hr HCV 
48 hr Mock 
24 hr HCV 
24 hr Mock 
8 hr HCV 
8 hr Mock 
RNA-seq 
A
B C
Figure 22. Increased expression of BMP binding endothelial regulator (BMPER) in 
HCV exposed LSEC. Panel A. Gene expression is displayed as the number of 
sequencing reads per kilobase of gene length per million reads (RPKM) using the 
Integrated Genome Browser (IGB). Panel B. and Panel C. show qPCR verification 
analysis of 9 additional HCV+/- and LPS +/- samples. 
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cytokines, and the loss of BMPER leads to inflammation primary due to enhanced 
BMP-induced NFКB activity.(95, 96) BMPER is regulated by transcription factor 
Krüppel-like factor 15 (KLF15), a gene commonly downregulated in endothelial 
dysfunction.(97) KLF15 was 2.1-fold increased in HCV infected LSECs. 
Furthermore, among genes related to BMPER function that are inhibited in 
endothelial dysfunction, NOS3 and NOSTRIN involved in NO synthesis, were 
upregulated in HCV infection, 1.5- and 2.0-fold increase, respectively.  
 
Many other transcripts enrolled in negative regulation of inflammatory and 
defense responses were significantly upregulated in HCV infected cells, such as: 
  
• C1QTNF1, C1q and tumor necrosis factor related protein 1 (3.7-fold 
increase) with anti-inflammatory and insulin sensing effects,(98)  
• NT5E, 5'-nucleotidase, 1.5-fold increase, that participates in the 
extracellular pathway that converts ATP to adenosine on the surface of 
various types of cells, therefore by increasing extracellular levels of anti-
inflammatory adenosine molecules;  
• APOE, apolipoprotein E (2.1-fold increase) primary synthesized in the 
liver that mediates inflammation independently of its role in lipid 
metabolism by modulating type I inflammatory responses;  
• IGF2, Insulin-like growth factor 2 (2.1-fold) with metabolic and growth-
promoting effects;  
• SERPING1, serpin peptidase inhibitor, clade G (C1 inhibitor), member 1 
(6.8-fold) a plasma protein that inhibits complement activation;  
• HPX, hemopexin (2.5-fold) a protector of cells from oxidative stress 
previously shown to diminish increase of TNFα and IL6 in LPS 
stimulated macrophages.  
Although partly contradictory, these results provide an interesting insight intro 
molecular mechanisms that might reduce inflammatory and promote anti-
inflammatory response in HCV infected LSECs that may answer questions 
regarding mechanism of HCV infection chronicity, relatively slow process of 
fibrogenesis, which is primary related to low level of tissue inflammation.  
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5.6. CHANGES IN TRANSCRIPTOME RELATED TO THE 
REGULATION OF ADAPTIVE IMMUNE RESPONSE 
 
Endothelial cells were recognized as critical in both limiting and enabling the 
trafficking of various immune cell populations out of the vasculature and into 
tissue. LSEC express and differentially regulate after HCV infection both class I 
(HLA-A 1.32x, HLA-B 1.75x, HLA-C 1.48x, HLA-E 1.70x, HLA-G 1.65x, HLA-H 
1.64- fold increase after HCV exposure) and class II MHC molecules. The 
expression of MHC class II molecules was significantly lower than class I, what is 
similar as previously reported on HUVEC model. Therefore LSEC are able to 
provide signal 1 to resting T cells. In addition, LSEC provide a variety of co-
stimulators.  
 
Of note, cultured human LSEC lack both CD80 and CD86 ligands for T cell 
activation (signal 2). Since CD80 and CD86 are considered as the prototypic co-
stimulators of T cell activation, this might suggest that LSEC are unable to provide 
second signal for T-cell activation in the setting of HCV infection. However, CD40, 
described as a possible co-stimulator of T cell activation, was 2.4-fold upregulated 
after HCV infection. TNFSF4, which produces a potent co-stimulatory signal for 
activated CD4+ T cells, was 1.9-fold decreased after HCV exposure.  
 
A negative co-stimulator of T-cell, Programmed cell death ligand 1 (PD-L1), 
was 1.3-fold decreased after HCV infection. It was shown that PD-L1 and PD-L2 
blocking results in increased endothelial transmigration by both CD4+ and CD8+ T-
cells.(99) While normal endothelium expresses PD-L2 and reduces tissue 
inflammation, PD-L1 and PD-L2 expression by endothelial cells from multiple 
sclerosis lesions was significantly reduced, suggesting an important role of these 
molecules in chronic inflammation.(99) These findings are in contrast to 
plasmacytoid DCs and myeloid DCs (mDCs) isolated from HCV-infected patients, 
where the effect of inhibitory marker PD-L1 overwhelmed the effect of co-
stimulatory markers and downregulated DC-T activation in HCV-infected 
patients.(100) Meanwhile, the increased interactions between PD-1(+) KCs and 
PD-L1(+) LSECs appear to lead to the decay of normal endothelial functions 
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critical to support vascular integrity and prevent acute liver failure as investigated 
at the model of murine sepsis, and this is probably independent of its normal, 
immune-suppressive activity.(101) 
 
Interestingly, several other T cell co-inhibitory ligands were significantly altered 
after HCV exposure. These include: 
  
• TNFRSF14 (or HVEM, 1.8-fold increased), a TNF superfamily of co-
stimulatory molecules, which bind to B- and T-lymphocyte associated 
(BTLA) co-inhibitory receptors. The interaction of TNFRSF14 with BTLA and 
multiple other ligands results in transmission of an inhibitory signal.(102) 
• Galectin 9 (LGALS9, 2.3-fold increased), recognized by T cell 
immunoglobulin-3 (TIM3) glycoprotein receptor, induces intracellular 
calcium flux, cell aggregation and the death of Th1 but not Th2 cells which 
provides a negative feedback loop to prevent uncontrolled harmful Th1 
responses.(102) 
 
While this occur through direct cell-cell contact, LSEC are armed with a variety 
of soluble inhibitory mediators through secretion of which might provoke immune 
suppression. This might include: 
  
• NOS3 (nitric oxide synthase 3), 1.5-fold increase, reported to induce 
apoptotic cell death in a variety of cells, and has been proposed to alter the 
responsiveness of T-lymphocytes to antigen or mitogenic stimuli.(103) 
• HPX (hemopexin), 2.5-fold increase, functions as an iron source for T-cells 
and is involved in the regulation of cell growth. It was suggested that 
hemopexin, by controlling heme-iron availability in lymphocytes, modulates 
responsiveness to IFN-gamma, which might have a negative regulatory role 
in Th17-mediated inflammation.(104) 
• IL33 (interleukin 33), 5.2-fold increased, which drives Th2-immune 
responses.(91) 
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The adhesion of leukocytes to vascular endothelium is a hallmark of the 
inflammatory process. These interactions are initiated by a variety of chemical 
mediators and the entire process of leukocyte–endothelial cell adhesion is 
regulated by the sequential activation of different families of adhesion molecules 
that are expressed on the surface of leukocytes and LSEC, as reviewed in (105, 
106). Lectin-like adhesion glycoproteins, called the selectins, mediate leukocyte 
rolling, while the firm adhesion and subsequent transendothelial migration of 
leukocytes are mediated by the interaction of integrins on leukocytes with 
immunoglobulin-like adhesion molecules on endothelial cells (e.g., ICAM-1, 
VCAM-1).(106)  
  
Inspection of the leukocyte transendothelial migration pathway revealed that 23 
of 113 genes were core enrichment genes, which included genes encoding for the 
following proteins: chemokine receptor CXCR4 and its ligand CXCL12, which 
activates through PI3K (encoded by PIK3CB and PIK3CG) and RAC2, eventually 
impacts cell motility; integrin ITGB1 (-1.4x) involved in cellular adhesion; 
transmembrane protein ICAM1 (+1.4x) that facilitates leukocyte endothelial 
transmigration; components of tight junction strands claudin -1 and -11 (CLDN1 -
3.7x, CLDN11 -1.6x), upregulated  claudin 5, -10 and -15 (CLDN5 +1.6x, CLDN10 
+1.5x, CLDN15 +1.4x), which also play critical roles in maintaining cell polarity and 
signal transductions; component of the hexameric ATPase cellular motor protein 
myosin 5 and 9 (MYL5 +1.3x, MYL9 +1.3x).  
 
Along the passage of ICAM1-mediated signals was the coordinated down-
regulation of PKC encoded by PRKCA (-2.9x) and upregulation of phospholipase 
C (PLCG2 +1.6x) required for ICAM1 dependent leukocyte migration. Along the 
VCAM1-mediated signal passage were down-regulation of PI3K encoded by 
PIK3CB (-1.4x) and PIK3CG (-3.1), downregulation of protein tyrosine 
phosphatase (PTPN11 -1.5x); upregulation of subunit of NADPH oxidase 
(encoded by CYBA, +1.5x) whose activation is required for the production of 
reactive oxygen species in a Rac-mediated manner (RAC2 -1.3x) with subsequent 
activation of matrix metallopoteinases and loss of VE-cadherin-mediated adhesion. 
Along the Thy-1-signal passage, except Thy1 cell surface antigen (+2.7x), other 
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signal transducer was downregulated, ROCK2 (-1.3x), activation of which leads to 
myosin phosphorylation, resulting in retraction of the actin cytoskeleton.  
 
After HCV infection selectin L, selectin P and selectin P ligand were 1.6-fold, 
3.2- and 5.5-fold increased, respectively. Intercellular adhesion molecule 1 (ICAM-
1) was 1.4-fold increased and vascular cell adhesion molecule 1 (VCAM-1) 1.6-
fold decreased. Interestingly, several endogenous anti-adhesion molecules were 
also significantly altered. These include: 
• NOS3 (nitric oxide synthase 3), 1.5-fold increase, whose inhibitors were 
shown to stimulate the recruitment of adherent leukocytes.(107) 
• Upregulation of the prostaglandin I2 (prostacyclin) synthase (2-fold 
increase), prostaglandin-endoperoxide synthase 1 (prostaglandin G/H 
synthase and cyclooxygenase, 1.5-fold increase) and phospholipase C (1.9-
fold increase), all involved in production of prostacyclin (PGI2). Activation of 
the PGI2 is a potent vasodilator and an inhibitor of platelet aggregation, 
leukocyte adhesion, and vascular cell proliferation 
• Thrombomodulin (1.6-fold increase) shown to directly inhibit leukocyte 
adhesion to activated endothelium by sequestering proinflammatory 
proteins.(108) Other member of the C-type lectin transmembrane family, 
endosialin, with similar function was significantly increased (2.6-fold 
increase) 
• Activated leukocyte cell adhesion molecule (ALCAM or CD166, 1.8-fold 
decreased), binds to T-cell differentiation antigene CD6, and is implicated in 
the processes of cell adhesion and migration 
These results might suggest a different means of LSEC regulation of adaptive 
immune response than previously thought. However, the model of primary cell 
LSEC culture does not provide appropriate model for the research of adaptive 
HCV immune response.  
 
 
 
 
! 56 
5.7. DOWN-REGULATION OF CELL CYCLE AND APOPTOSIS 
PATHWAYS 
The cell cycle pathway was significantly downregulated in HCV exposed LSEC 
and the coordinated down-regulation of these genes appeared in all phases of cell 
cycle including G1 to S, G2 to M, and metaphase to anaphase transition. Down-
regulated genes encoding for proteins for G1 to S transition included: CDNK2B, 
cyclin-dependent kinase inhibitor; CCNE1 encoding for cyclin E; CDC7 cell division 
cycle 7. Downregulated were genes essential for genome replication and 
regulation of transcription CDK6 and CDK7, encoding for cyclin-dependent kinase 
6 and 7; mini-chromosome maintenance (MCM) complex (gene MCM4, 6) 
essential for the initiation of eukaryotic genome replication. These most likely 
represent the coordinated alteration as the down-regulation of the core enrichment 
genes directly involved in the transition promotion implicates G1/S arrest. In the 
G2 to M transition, the down-regulation of CCNA1 and CCNB1 (cyclin A and B) 
was observed. Genes encoding proteins that promote the activity of CDK1 
complexes including CDC25A, -B, and -C, were not significantly altered, which 
may implicate G2/M arrest. Additionally, genes involved in DNA damage 
checkpoint were coordinately down-regulated in the such as CHEK1, ATR and 
ATM. Genes involved in activation of the activation of the anaphase promoting 
complex/cyclosome (BUB1, BUB3, BUB1B, MAD2), and components of 
anaphase-promoting complex (ANAPC1 and CDC27), were also significantly 
down-regulated.  
 
Closely associated with the cell cycle was the apoptosis pathway. While LPS 
induced major changes in both pro- and anti-apoptotic pathway, mainly suggesting 
induction of apoptosis, HCV induced minor changes that implicated inhibition of 
apoptosis after HCV infection. To examine the impact of HCV infection and LPS 
stimulation on the cells, we measured the cell death and apoptosis at 24 and 48 
hours post-exposure. As shown in Figure 25., there was no difference in the 
percentage of dead or apoptotic cells between MOCK or HCV infected cells. 
However, the LPS exposed cells had significantly increased level of cell death and 
apoptosis. This supports transcriptome changes in key transcripts in apoptosis and 
cell death pathways.  
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Figure 23.  Downregulation of cell cycle pathway in HCV infected LSEC. Downregulated genes are shown in blue and upregulated in red. 
Fold changes of LPS stimulated LSECs are shown in orange (upregulated) and green (downregulated), dashed brackets.  
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Figure 24.  Activation of apoptosis pathway in LPS exposed LSEC cultures. Downregulated genes are shown in blue and upregulated in red. 
Fold changes of HCV exposed LSECs are shown in orange (upregulated) and green (downregulated), dashed brackets.  
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5.8. LSEC RESPONSE TO HCV INFECTION MIGHT PLAY 
DUAL ROLE IN LIVER REMODELING AND 
FIBROGENESIS.  
 
Significant number of DEGs (and Kegg pathways) was related to blood vessel 
development.(109) The formation of new vessels and the establishment of an 
abnormal angioarchitecture of the liver is a process strictly related to the 
progressive fibrogenesis. The process of liver remodeling typical for chronic viral 
hepatitis was illustrated by an overexpression of several growth factors, cytokines 
and metalloproteinases that have been shown to exert a potent profibrogenic role 
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Figure 25. Level of apoptosis 
and cell death after HCV and 
LPS exposure in LSEC, as 
measured by Annexin V/7-AAD 
staining (details in Methods).  
LPS stimulated LSEC exhibit 
higher level of apoptosis as 
compared to controls.  
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and stimulate LSEC proliferation and migration.(109) However, RNA-seq analysis 
revealed downregulated vascular endothelial growth factor (VEGFC, 2.1-fold, 
Figure 20), angiopoietin 2 (ANGPT2, 1.5-fold), fibroblast grow factor 5 (FGF5, 1.6-
fold), and 16 (FGF16, 2.1-fold), all playing crucial role in angiogenesis.  
 
 
VEGF-driven responses in endothelial cells are considered to be a crucial in 
both physiologic and pathologic angiogenesis. Upregulation of transcripts involved 
in cell growth and survival (PLCG2, SHC2, BAD), actin organization and cell 
migration (NOS3, MAPK11, MAPK12, HSPB1) was observed after HCV infection.  
 
Figure 26. Decreased expression of VEGFC in HCV exposed LSEC. Panel A. Gene 
expression is displayed as the RPKM using the Integrated Genome Browser (IGB). 
Panel B. and Panel C. show qPCR verification analysis of 9 additional HCV+/- and 
LPS +/- samples 
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Figure 27.  Enrichment of VEGF signaling pathway in HCV infected LSEC. Downregulated genes are shown in blue and upregulated in red. 
Fold changes of LPS exposed LSECs are shown in orange (upregulated) and green (downregulated), dashed brackets.  
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Several members of metalloproteinase family were also downregulated in 
addition to previously described absence of potent inflammatory response and 
changes in pro‐inflammatory cytokines (e.g. TNF‐α, IL‐1, IL‐6) that have been 
shown to stimulate angiogenesis. In contrast, several transcripts involved in 
endothelial invasion were significantly upregulated. Aquaporins are proteins 
embedded in the cell membrane that regulate the flow of water.(110, 111) 
However, they play an important role in cell migration and invasion that may 
contribute to angiogenesis and cirrhosis.(112, 113) Interestingly an AQP single-
nucleotide polymorphism was recognized as part of a genetic signature that can 
identify patients at risk for HCV disease progression to cirrhosis.(114)  
 
 
Aqupaorin 1 (AQP1) 
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Figure 28. Increased expression of AQP1 in HCV exposed LSEC. Panel A. Gene 
expression is displayed as the number of sequencing reads per kilobase of gene length 
per million reads (RPKM) using the Integrated Genome Browser (IGB). Panel B. and 
Panel C. show qPCR verification analysis of 9 additional HCV+/- and LPS +/- samples. 
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We found upregulated several members of aquaporin family, such as AQP1, 
AQP3, AQP5 with 6.23-, 4.02-, 2.31-fold increase, respectively. We confirmed 
upregulation of AQP1 with qPCR analysis on 27 additional samples. Interestingly, 
all AQP1, AQP3, AQP5 were significantly downregulated in LPS stimulated LSECs 
(3.0-, 2.1-, 2.0-fold decrease, respectively) suggesting that upregulation of AQPs 
contributes to HCV specific liver pathology.  
 
Role of the LSECs in liver fibrosis has been controversial. Since changes in 
LSEC can be detected significantly before fibrosis is microscopically visible it was 
suggested that LSEC might drive or even initiate fibrosis, particularly in the early 
stages before hepatic stellate cells undergo myofibroblastic differentiation. RNA-
seq results suggest that LSEC may be involved in liver fibrosis on several different 
levels.(115) 
 
First, we found upregulated several transcripts coding for basement membrane 
glycoproteins, such as collagen IV (COL4A1 2.1- and COL4A2 1.25-fold increase), 
laminin (LAMB2 1.3-fold increase), enactin (NID1 1.27- and NID2 2.15-fold 
increase), lectins (LGALS3BP 1.96-, LGALS9 2.32-fold increase), aggrecan 
(ACAN 2.68-fold increase), thrombospondins (THBS2 1.95- and THBS3 1.51-fold 
increase). Integrins (ITGB2 2.7, ITGA2 2.3, ITGB8 2.2, ITGAV 1.9-fold decreased), 
which play major role LSEC activation, were significantly decreased. In addition, 
gap junction molecules were upregulated after HCV infection (such as GJA4 2.56- 
and GJA5 2.1-fold increase). Upregulation of these transcripts might suggest 
capillarization, loss of fenestrations and formation of an organized basement 
membrane in the Space of Disse that has been recognized as one of the hallmarks 
of liver fibrosis. Moreover, it appears that HCV by itself is sufficient to induce these 
changes in the absence of signals from surrounding cells in liver 
microenvironment.  
 
Second, many transcripts coding the fibrillar collagens were upregulated 
(COL1A 2.56-, COL1A2 1.48-, COL3A1 1.77-, COL5A3 2.15-, COL6A1 2.55-, 
COL6A2 3.02-. COL6A3 2.13-, COL7A1 2.4- fold increase). Although stellate cells 
are main source of extracellular matrix (ECM) synthesis and deposition,(116) our 
! 64 
study showed that LSECs can synthesize these molecules and participate in ECM 
deposition.  
 
Third, we found more than 130 DEGs related to cell adhesion and ECM-cell 
interaction (such as SELPLG 5.44- and SELP 3.26-, ITGB4 3.26-, ITGA9 2.57-, 
PCDHB7 2.56- SPON2 2.55-, NLGN3 2.51-, ADAMTS13 2.43- fold increase). 
Many of these DEGs are coding for soluble, secreted molecules that are involved 
in regulation of inflammatory, angiogenic and fibrogenic processes and has not 
been previously related with HCV infection (such as CLEC3B 4.1-, MATN2 3.2-, 
SMOC1 2.1-, TNXB 2.6- fold increase).  
 
Forth, some of the enriched Kegg pathways (e.g. Peroxisome proliferator-
activated receptors (PPAR) signaling pathway, ECM-receptor interaction, Renin-
angiotensin system) are involved in fibrosis progression. Angiotensin I converting 
enzyme (ACE) was upregulated 3.4-fold in HCV infected LSECs, but not in LPS 
stimulated LSECs (1.6-fold decrease). Recent studies have shown that the renin-
angiotensin system (RAS) plays a pivotal role in liver fibrosis and the clinically 
used angiotensin-converting enzyme (ACE) inhibitor (ACE-I), and AT1-R blockers 
(ARB) significantly attenuated experimental liver fibrosis.(117, 118)  
 
However, the efficiency of these changes and contribution to the fibrosis 
development is unclear. At the same time pathways like TGFβ and inflammatory 
molecules are downregulated, suggesting that fibrotic role of LSECs could be 
more complicated in in vivo environment.  
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5.9. CHANGES IN KEGG PATHWAYS IN HCV INFECTED LSEC 
 
In order to further investigate and visualize genes interaction, the RNA 
sequencing database of differentially expressed genes was analyzed to determine 
which of the 228 KEGG pathways were significantly enriched (altered) during HCV 
infection in LSECs. We identified a total of 31 significantly enriched pathways 
(Table 7.) The majority of enriched KEGG pathways were observed at 48 hours 
after infection. 
KEGG PATHWAY 8h 24h 48h 
DEGs  p 
value 
DEGs  p 
value 
DEGs  p value 
RIG-I-like receptor signaling pathway     16 0.04 
Cytokine-cytokine receptor interaction   8 0.04 50 0.02 
Complement and coagulation 
cascades 
  4 0.02   
Leukocyte transendothelial migration     24 0.05 
Fc gamma R-mediated phagocytosis     21 0.03 
Lysosome     28 <0.001 
Cell adhesion molecules (CAMs)   5 0.05 34 <0.001 
Focal adhesion   7 <0.001 47 <0.001 
Axon guidance 13 <0.001 5 0.04 35 <0.001 
TGF-beta signaling pathway     19 0.04 
MAPK signaling pathway     49 0.05 
Cell Cycle     30 <0.001 
VEGF signaling pathway     17 0.04 
Hematopoietic cell lineage     19 0.04 
Renin-angiotensin system     6 0.03 
PPAR signaling pathway   4 0.02 18 <0.001 
ECM-receptor interaction   4 0.03 29 <0.001 
Ubiquitin mediated proteolysis 10 0.03     
ABC transporters   5 <0.001   
Apoptosis     19 0.04 
mTOR signaling pathway 5 0.05     
p53 signaling pathway 6 0.04   16 0.03 
Wnt signaling pathway 10 0.05     
Pathways in cancer 29 <0.001   61 0.02 
Basal cell carcinoma 6 <0.001     
Pancreatic cancer 7 0.01     
Bladder cancer 5 0.02     
Small cell lung cancer 7 0.03   20 <0.01 
Amino sugar and nucleotide sugar 
metabolism 
    13 <0.001 
Other glycan degradation     6 <0.01 
Purine metabolism     31 0.03 
 
Table 7. List of enriched KEGG pathways (Kyoto Encyclopedia of Genes and Genomes). 
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Enriched were KEGG pathways related to cell scavenger functions (e.g. Fc 
gamma R-mediated phagocytosis, Cell adhesion molecules, Focal adhesion, 
Leukocyte transendothelial migration, Axon guidance), innate immune responses 
(RIG-I-like receptor signaling, cytokine-cytokine receptor interaction, complement 
and coagulation cascades) and cancer development (Pathways in cancer, 
Apoptosis, p53 signaling, Wnt signaling). 
 
The TGFβ signaling pathway was previously reported deregulated during acute 
HCV infection and regulates cell cycle arrest, apoptosis, and fibrosis under 
experimental conditions.(10, 62) Interestingly, pathways that might be involved in 
fibrosis progression (e.g. PPAR-signaling pathway, ECM-receptor interaction, 
Renin-angiotensin system) were also significantly altered. 
. 
Figure 29. Panel A. Gene expression is displayed as the RPKM using the Integrated 
Genome Browser (IGB). Panel B. and Panel C. show qPCR verification analysis of 9 
additional HCV+/- and LPS +/- samples. 
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Furthermore, in closer look to the gene changes within the specific pathways, 
some of them are differently regulated than in other cell lines, such as TGFβ/BMP 
that is upregulated in Huh 7.5 cells. In addition to downregulated TGFB2 (2.5- fold 
decrease, Figure 29.), we found significantly downregulated SMAD family 
members, SMAD3 and SMAD5 (1.5- and 1.4-fold decrease, respectively) 
important for signal transduction. Furthermore, inhibitory SMAD6 and SMAD7 
were upregulated 1.4- and 1.25-fold, and transcriptional target of TGF-β/BMP 
signaling, RUNX1 transcriptional factor, was downregulated 2.1-fold. Genes 
involved in TGF-β trafficking and activation LTBP1 and LTBP2 were significantly 
downregulated, both 1.6-fold. These data suggest that TGF-β pathway is inhibited 
n HCV infected LSECs on several different levels (Figure 30.).  
 
Figure 30. Enrichment of TGF-β signaling pathway 48 hours after HCV exposure 
 
! 68 
Interestingly, several pathways and more than 100 DEGs were directly related 
to cytoskeleton reorganization or vesicle mediated transport. Fc gamma R-
mediated phagocytosis plays an essential role in host defense response through 
the uptake and destruction of infectious pathogens. In addition, Cell adhesion 
molecules, Focal adhesion, Leukocyte transendothelial migration and Axon 
guidance pathways play important roles in biological processes including cell 
motility, proliferation, differentiation, regulation of gene expression and cell 
survival. Signaling events of these pathways culminate in reorganization of actin 
cytoskeleton and membrane remodeling. These processes may be hijacked by 
HCV to facilitate its infectivity and entry into relatively safe intracellular 
environment. LSECs may use them as a detour for activating gene expression in 
the presence of inefficient PRR-signaling that does not result in the activation of 
the inflammatory responses. 
 
Since it was reported that HCV utilizes endocytosis pathway to escape 
lysosomal degradation,(57) we examined related pathways. In Fc gamma R-
mediated phagocytosis pathway, transcripts involved through the actin 
cytoskeleton rearrangements and membrane remodeling to the formation of 
phagosomes were significantly upregulated. These include: Dynamin 1 (DNM1, 
+1.9x), MARCKS-like 1 (+1.5x), phospholipase A2 (encoderd by PLA2G6, +1.8x), 
regulator of actin polymerization encoded by TTLL3 (+1.7x) and gelosolin (+2.1x). 
Furthermore, several lysosomal acid proteases were significantly upregulated: 
cathepsins (CTSA +1.4x, CTSC -1.4x, CTSD +1.6x, CTSF +2.0x, CTSH +1.5x, 
CTSL2 +2.1x), glycosidases (GAA +2.0, IDUA +1.8x, HEXA +1.4x, NEU1 +1.3x), 
sulfatases (ARSA +1.5x, ACP2 +1.4, ACP5 9.1x). Meanwhile clathrin (CLTC -
1.34x), lysosomal structural proteins (NPC1 -1.4x, LAMP3 -1.5x) and AP4E1 (-
1.5x) were downregulated. Upregulated were also genes coding for early and late 
endosome (FAM125A 1.4x, VPS28 1.4x, VPS37D 2.0x, EHD3 1.7x).  
 
Surprisingly the only pathway enriched at all time points was axon guidance. 
Axon guidance represents a key stage in the formation of neuronal network and 
involves a variety of guidance factors, such as semaphorins. However, 
accumulating evidence indicates that several semaphorins play additional diverse 
roles in unrelated processes to axon guidance, including organogenesis, 
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vascularization, angiogenesis, neuronal apoptosis, and neoplastic 
transformation.(119) Moreover, newly recognized “immune semaphorins”, are 
crucial to various phases of the immune response, from initiation to terminal 
inflammatory processes.(119, 120) The Figure 31 shows changes in mRNA levels 
of molecules within sempahorins signaling pathway (as a part of the axon 
guidance pathway) in HCV infected LSECs.  It seems that final outcome of 
semaphorins signaling could be inhibition of pathway on receptor or downstream 
levels. Interestingly, semaphorins can exist in membrane-bound and soluble form, 
which can target immune cells.(119, 120)  
 
Examples include:  
• SEMA3A (2.1-fold decrease) known to inhibit spontaneous monocytic 
cell migration.  
• SEMA4A (2.4-fold increase) that can provide T cell costimulation and 
the induction of either Th1-cell-mediated IFN-γ production or Th2-cell-
mediated IL-4 production, depending on the respective culture 
conditions.  
• SEMA6B (1.4-fold increase) that might bind to and activate dendritic 
cells and increase type I interferon production.  
• SEMA7A (2.6-fold increase) stimulates monocytes/macrophages to 
provoke proinflammatory cytokine production. 
So far semaphorins have not been related with HCV infection. 
 
In our previous study on HCV infected Huh 7.5 cells we found upregulated 
several semaphorins (such as SEMA3B 2.4, SEMA4C 1.5, SEMA6A 1.7, SEMA7A 
3.2) and their receptors (PLXNA1 1.9-, PLXNA3 2.0-, PLXNB1 1.3-, PLXNAB2 1.6-
fold). Similarly, SEMA3C, SEMA4A and SEMA6B were upregulated in HCV 
infected TPH-1 cells (16.5-, 2.2- and 18.5- fold). This suggests an important, 
previously unexplored role of these molecules in HCV pathogenesis 
 
. 
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Figure 31. Enrichment of “semaphorins” pathway signaling 48 hours after HCV exposure. 
Downregulated genes are shown in blue and upregulated in red boxes. Green boxes show 
fold changes 72h after HCV infection of Huh7.5 cells, and orange 16 hours after HCV 
infection of THP-1 cells.  
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5.10. LSEC, HEPATOCYTES AND KUPFFER CELLS MIGHT 
PLAY DISTINCT ROLES DURING HCV INFECTION 
 
Applying the system biology approach to determine the drivers of inflammation 
in HCV infected liver, a comprehensive RNA sequencing gene expression analysis 
of models of hepatocytes (Huh 7.5 cells), substitute model of Kupffer cells (THP-
1), primary human LSECs, plus mild (inflammation but no fibrosis) and severe 
(cirrhosis) chronic hepatitis C liver specimens were performed.(10, 26, 27) This 
helped to identify distinct gene expression profiles in HCV infected LSECs, KCs 
and hepatocytes, suggesting their different roles during HCV infection. 
 
 
 
 
Figure 32. Differentially expressed genes after HCV infection of Huh 7.5, THP-1 and 
LSEC cell cultures including the most enriched GO-pathways representative to each cell 
type. 
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5.10.1. KUPFFER CELLS DRIVE INFLAMMATORY RESPONSES 
IN CHRONIC HEPATITIS C 
 
RNA-seq analysis of HCV infected THP-1 cells revealed a broad and complex 
cellular transcriptional reprograming in wide range of gene functional categories. 
Analysis of differentially expressed genes (DEGs) identified 4050 and 3079 
significantly altered genes in THP-1 cells at 6 and 16 hours post HCV-exposure, 
respectively. In contrast to similar studies on hepatoma cell lines and LSEC, where 
the overall effect of HCV infection on cellular gene expression was subtle in the 
early phases of infection, in macrophages fold change ranges from 324-fold 
increase of CTGF (connective tissue growth factor) to 60-fold decrease of DHRS9 
(dehydrogenase/reductase (SDR family, member 9). 
 
Similarly as in LSEC, THP-1 cells do not support viral replication, so these 
changes are not related with HCV replication cycle, viral titer or presence of 
dsRNA, as in Huh 7.5 cells where the host transcriptional response corresponds 
closely to the levels of HCV replication. Interestingly, in comparison to acutely 
infected Huh 7.5 cells, approximately 80% of changed transcripts were unique for 
KCs. In addition, HCV-activation of KC results in the release of an array of 
inflammatory and immune mediators.  
 
Several hundreds of genes participate in the inflammatory response and their 
coordinated expression is tightly regulated. Most of these genes share some 
remarkable features regarding their role in biosynthesis and degradation of 
inflammatory mediators. This includes a dramatic and broad increase in IL-1β (81-
fold increase 16h after HCV exposure in contrast to 27-fold increase after LPS 
stimulation) and NFκB responsive proinflammatory cytokine and chemokines 
expression (such as IL12, 132-increase; IL8, 38x; MIP1b or CCL4, 34x; MIP1a or 
CCL3, 24x; CCL22 176x; CXCL1 100x, CXCL2 68x, LIF 48x; CSF3 189x). 
Meanwhile, modest increases in anti-inflammatory cytokines occurred (IL10 16x; 
IL1RN 7x; IL11 15x; TNFRp75 3x). Interestingly, this significantly correlated with 
LPS stimulated cells, therefore suggesting a similar pattern of inflammatory 
response, in contrast to LSEC. Importantly, in comparison with chronic hepatitis C 
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liver specimens, the expression of this gene correlated with disease severity. 
These observations imply that in patients with chronic hepatitis C, Kupffer cells 
and/or infiltrating liver macrophages produce IL-1β, driving a hepatic response that 
includes the expression of a wide range of proinflammatory mediators of liver 
inflammation, fibrogenesis and disease. 
 
 
."
 
 
 
Figure 33. Cluster map showing the expression of genes linked with inflammation in THP-
1 cells and in chronic HCV livers. Selected genes that were commonly expressed in both 
THP-1 cells and chronic HCV livers are shown in table.  
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Unlike RNA-seq analysis of macrophages, HCV did not induce a marked 
increase in such inflammatory signals in both LSECs and Huh7.5 cells. In contrast, 
HCV in general induced a downregulation of inflammatory signals in LSEC. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 34. Differentially expressed genes (Gene Ontology: Immune response) in THP-1 
and LSECs cultures. Venn diagram shows a different pattern of gene expression in THP-1 
and LSECs. Examples of significantly changed genes are shown in tables. 
 
 
Thus, selective dysfunction of KC and LSEC might be relevant by profoundly 
affecting the immune responses against HCV at the level of the infection site. 
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5.10.2. TRANSCRIPTIONAL RESPONSE IN HCV INFECTED 
HEPATOCYTES 
 
RNA-seq analysis identified 100, 684, and 1,844 significantly differentially 
expressed annotated genes in acutely infected Huh 7.5 cells at 6, 48, and 72 
hours, respectively. The number of differentially expressed genes correlated 
closely with HCV replication, which was not the case in both THP-1 and LSEC 
cultures.  
 
Gene ontology analysis of those, identified major changes within regulation of 
transcription, RNA processing, metabolism, signaling, cell cycle and apoptosis 
pathways (Figure 35.). Significantly, a subset of genes within these pathways was 
similarly regulated in HCV-infected livers and their expression correlated with 
fibrosis level. Meanwhile, only small changes within inflammatory cytokine-
chemokine networks were observed.  
 
Figure 35. Gene ontology analysis of HCV infected Huh7.5 cells. 
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Furthermore, a significant number of altered genes is coding for a building 
blocks of the cell membrane, cytoskeleton, endoplasmic reticulum and nucleus.  
Figure 36. Functional analysis of DEGs in HCV infected Huh7.5 cells. 
 
This is suggesting that in order to establish efficient and persistent infection, 
HCV rearrange cytoskeleton and membranes that are required for formation of 
replication complex. Follow up studies on some of these genes supports this 
concept. Silencing of fucosyltransferase 1 (FUT1, involved in protein glycosylation) 
in Huh 7.5 cells inhibited HCV RNA replication by up to 80% of controls and 
infectious virion production was inhibited by 50%.(10) Similarly, silencing of kelch-
domain containing 7B (KLHDC7B, regulates protein-protein interactions), inhibited 
HCV RNA replication and virion production by 70%.(10)  
 
Pathways regulating cell-survival, proliferation and growth responses (insulin 
signaling, Notch signaling and c-myc pathways) were significantly enriched as well 
as did the pathways stimulating apoptosis and cell death. Since all these changes 
are growing demand for energy, alternation of metabolic pathways (such as insulin 
signaling, amino acid and lipid metabolism) was not surprise.   
 
These results suggest, that HCV has developed mechanisms to subvert this 
aspect of the host antiviral response to establish a safe harbor for replication and 
viral persistence.  
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5.10.3.  LIVER SINUSIDAL ENDOTHELIAL CELL SPECIFIC 
PATHWAYS IN CHRONIC HEPATITIS C LIVERS 
 
A global transcriptome analysis of RNA recovered from liver biopsies of normal 
control (donor) or chronic HCV-infected livers of patients staged according to mild 
(mild inflammation and no fibrosis) or severe (cirrhosis undergoing liver 
transplantation) disease was performed, and the list of differentially expressed 
genes was compared with LSEC-RNAseq data. Total of 633 DEGs were 
commonly expressed in LSEC and mild, and 671 in LSEC and cirrhotic livers.  
 
 
 
 
 
 
 
Figure 37. Differently expressed genes 
(DEGs; FDR.13 and fold change ≥1.5) 
HCV+/LSECs, mild chronic hepatitis C 
(CHC) (HCV+, no fibrosis) and severe 
CHC (HCV+, cirrhotic liver 
biospecimens. 
 
 
Majority of these genes were involved in regulatory pathways including: 
regulation of cell proliferation and migration (84 DEGs), adhesion (70 DEGs), 
response to wounding (50 DEGs), defense response (46 DEGs). The list of 
commonly expressed Gene Ontology terms is shown in Figure 38. 
 
Significantly, the integration of the in vitro and patient liver gene expression 
data also suggests that these processes contribute to liver disease 
progression.  Interestingly, the increased expression of a subset of these genes 
appeared to be associated with liver disease progression.  
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Figure 38. Gene Ontology analysis shows significant overlap of pathways between 
chronic livers and LSECs. 
 
 
Collectively, these data demonstrate that, despite JFH-1 being somewhat of an 
atypical HCV, transcriptional changes which occur in HCV-infected LSEC parallel 
those which occur specifically during fibrosis development in HCV-infected 
patients. 
 
Since previous reports suggested that LSEC acquire enhanced immunogenicity 
in the setting of liver fibrosis related to the establishment of an abnormal 
angioarchitecture,(41) we examined the expression of key transcripts involved in 
angiogenesis and vasculature remodeling in liver biospecimens.  
 
The VEGF/VEGFR pathway is a key mediator of angiogenesis.(109) We found 
increasing expression of VGEFA and VGEFC with level of fibrosis (VGEFA 1.2-fold 
decrease vs. 2.6-fold increase in cirrhotic livers, and VGEFC 1.4-fold decrease vs. 
1.6-fold increase). Similarly, TGFβ was significantly upregulated in cirrhotic livers 
(TGFB2 13.5-fold, TGFB1 2.6-fold), while not significantly altered in mild fibrosis.  
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Several angiopoietins were significantly changed. In mild fibrosis, Angiopoietin-
like 3 (ANGPTL3,), which induces endothelial cell migration and cell adhesion, was 
2.5-fold increased. Meanwhile, in cirrhotic liver Angiopoietin 2 (ANG2) was 3.6-fold 
increase. ANG2 functions as an autocrine-acting, antagonistic ligand of the vessel 
maturation and remodeling by controlling ANG1 signaling axis. As such, ANG2, 
being almost exclusively produced by endothelial cells and function as a vessel-
destabilizing molecule that facilitates the activities of other cytokines involved that 
promotes or constrains angiogenesis. Interestingly, ANG2 was identified as an 
autocrine regulator of endothelial cell inflammatory responses, by permitting the 
activation of endothelial cells by proinflammatory cytokines.(121) 
 
Thrombomodulin (THBD), involved in angiogenesis by regulating the ability of 
endothelial cells to proliferate, invade, and adhere to each other, was 
downregulated in mild (4.2-fold), and not changed in cirrhotic livers.(122) 
Meanwhile, Thrombospondin (THBS1) was downregulated in mild (5.3-fold), but 
upregulated in cirrhotic livers (9.53-fold), as well as other THBS2 (4.4-fold). They 
serve as inhibitors of angiogenesis through direct effects on endothelial cell 
migration and survival.(123)  
 
One of the highly upregulated transcripts in cirrhotic livers was RGC32 
(Response gene to complement 32), 20.8-fold increased. RGC32 is induced by 
activation of complement and regulates cell proliferation and is recognized as an 
antiangiogenic factor in endothelial cells.(124)  
 
CMA1 (chymase 1) was upregulated 9.7-fold. CMA1 is in blood vessels, rather 
than angiotensin converting enzyme, largely responsible for converting angiotensin 
I to the vasoactive peptide angiotensin II that induces angiogenesis.(125) 
 
The abundance of these transcripts confirms the important role of LSEC in 
disease progression and pathogenesis.  
! !
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6. 
DISCUSSION 
 
 
This study represents the first comprehensive snapshot into the liver sinusoidal 
endothelial cell transcriptome by investigating the global dysregulation of the 
biological pathways in HCV and LPS exposed primary human LSEC. The main 
objective of the study was to identify genomic signatures associated with immune 
response in LSEC triggered by HCV, in order to increase our understanding of the 
HCV disease development.  
 
Changes in gene expression revealed a broad and complex cellular 
transcriptional reprograming in wide range of gene functional categories and many 
of these DEGs haven't been previously linked with HCV infection. Importantly, as 
LSEC cells do not support viral replication, these changes should not be related 
with HCV replication cycle, viral titer or presence of dsRNA, as in hepatocytes 
where the host transcriptional response corresponds closely to the levels of HCV 
replication. Interestingly, other characteristic of HCV induced LSEC transcriptome 
changes was a significant downregulation of gene expression, which was not the 
case in LPS stimulated cells, especially since downregulation of genes is relatively 
uncommon event in gene expression analysis. This might suggest a different 
pattern of gene reprograming as a special characteristic of LSECs, where cells 
shut down their normal functions that can benefit or limit virus infectivity. Indeed, in 
the HCV exposed cells, the key innate immune response pathways were 
significantly downregulated (such as RIG-I and TLR-signaling pathways), which 
correlated with the expression of inflammatory mediators. Notably, HCV infection 
induced completely diverse gene expression profiles in LSEC, hepatoma and 
monocyte cell cultures, suggesting LSEC’s unique role in disease pathogenesis   
 
Our data indicated that several hundreds of genes participate in the immune 
response and their coordinated expression is tightly regulated. These genes can 
be grouped into subsets as coding for various transcription factors (NUPR1, IL33, 
HEYL, MAF), cytokines and chemokines (CXCL1, CXCL2, IL8, CCL2, LIF), cellular 
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growth factors (VGEFC, FGF, TGFB2) and corresponding receptors (CD40, IL6R, 
IL3RA, FLT4, EGF4), as well as those coding for adhesion molecules (SELP, 
SELE, ICAMs). Expression patterns of the most of those genes share some 
remarkable features regarding their role in the modulation of inflammatory 
responses. In addition, we found 31 significantly enriched pathways. Since the 
immune-related pathways have the most direct relevance to the immune 
dysfunction characterizing HCV disease and this aspect has been under constant 
investigations, my discussion centered on the immune-related pathways top-
ranked by our analysis.  
 
The primary function of innate immunity is to recognize pathogen-associated 
molecular patterns (PAMPs) through pattern recognition receptors (PRRs).(11) 
Genome profiling of LSEC revealed expression of a large repertoire of PRRs, 
indicating a broad sentinel function, as previously reported in microarray analysis 
of murine LSEC cultures. Of those, TLR- and RIG-I system represent an important 
category of pathogen recognition receptors that are crucial in the first-line defense 
and are also important for modulating the adaptive immune response.(11-13) At 
the transcriptome level, the overall down-regulation of the PRR- signaling 
pathways manifested by the decreased TLR4 and intracellular sensors of double-
stranded RNA, RIG-I and PK3 expression with subsequent tuning down of the 
expression of the genes encoding for adaptor proteins, JAK-STAT, NF-κB and IRF 
signaling cascades, which resulted in the reduced expression of cytokine genes 
and reflected the deficiencies of innate immune response in HCV+ LSEC cultures. 
In contrast, LPS (TLR4 agonist) stimulation shows the ability of LSEC to initiate 
inflammatory response. 
 
The possible link between HCV infection and PRRs expression was suggested 
by the finding that specific agonists stimulated myeloid and plasmocytic dendritic 
cells from HCV-infected patients induced a significantly lesser amounts of IFNβ, 
TNFα and IL-12 than those from the healthy counterparts.(126, 127) This implies 
that alteration of the TLR/RIG-I system is instrumental in impairment of innate 
immunity in HCV infection. 
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Furthermore, the importance of TLR-signaling pathway was suggested in 
previously published study that showed TLR3 agonists could induce antiviral 
mediators by LSEC and inhibit murine encephalo-myocarditis virus replication 
(EMCV, a positive sense, single-stranded RNA virus).(128) This raises the 
question if PRRs’ ignorance of HCV in LSEC, enables undisturbed HCV replication 
in underlying hepatocytes. Recently, it was suggested that paracrine signals from 
LSEC could stimulate HCV replication.(129) JFH-1 replication in Huh7.5 cells in 
the presence of conditioned media from HCV non-infected LSEC cultures was 
significantly enhanced.(129) Since LSEC are the first cells exposed to the HCV 
entering the liver, it remains unanswered if the same effect would be observed with 
the media of HCV exposed LSEC.  
 
The down-regulation of the genes encoding for IRF3/7 arm of the TLR/RIG-I 
pathways is of particular interest as it plays crucial role in activation of IFNs 
transcription. Although the capacity of cultured endothelial cells to produce 
interferons (IFNs) was previously described,(130, 131) in LSEC expression of 
types I interferon and interferon-stimulated genes was unaffected after HCV 
exposure, at least for the time-points used in this experiment. The ability of HCV to 
dampen IFN-responses is well described. While transcriptome analysis of liver 
homogenates from chimpanzees with chronic HCV infection revealed a strong 
induction of hundreds of ISGs, the situation is more complex in patients with 
CHC.(132) 50%-70% of Caucasian patients show very little or no induction of 
ISGs, whereas the remaining 30%–50% have a permanent high-level expression 
of hundreds of ISGs.(133, 134) Paradoxically, activation of the endogenous IFN 
system in the liver seems to be ineffective against HCV and is related with 
negative response to IFN-based treatment.(135) In addition to inhibited TLR/RIG-I 
pathways, the possible explanation of IFN-system inhibition might include changes 
in transcriptional factors, expression of inflammation and immune system 
inhibitors.  
 
The changes in gene expression are usually driven by transcription factors, 
which are master-control proteins regulation activation and/or suppression of gene 
expression through binding to specific regulatory sequences of target genes. Our 
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transcriptomic analysis identified upregulated transcription factors essential for 
induction of anti-inflammatory state, such as MAFB, NUPR1, IL33, KLF15.   
 
The member of Maf family, v-maf musculoaponeurotic fibrosarcoma oncogene 
homolog B (MAFB), was shown to be a constitutive inhibitor of the type I interferon 
pathway.(77) Interestingly, it was shown that during the acute phase of viral 
infection, MAFB expression decreases, which allows activation of IFNβ 
transcription and subsequent antiviral activity.(78) The prolonged poorer 
expression of MAFB leads to the hyperactivation of IFNβ that might induce the 
development of autoreactive immune cells, therefore playing a possible role in 
mechanism of autoimmunity.(77) In contrast, if high MAFB expression is 
sustained, IFNβ expression is insufficient, which results in vulnerability to viral 
infection.(77, 78) In addition to disrupting IFNβ-enhanceosome, MAFB might 
suppress transcription of RANTES.(77, 78) MAFB was 2-fold upregulated in mild, 
but not significantly changed in cirrhotic livers, which corresponded with the 
observed level of ISG expression in liver samples.   
 
NUPR1, nuclear protein, transcriptional regulator 1, is stress-induced protein, 
implicated in diverse functions, including transcription regulation, modulation of 
apoptosis and autophagy, and cell cycle regulation.(79, 80) NUPR1 
overexpression is additionally associated with tumor progression.(79) The 
upregulation of NUPR1 in acute pancreatitis was correlated with the ability of the 
defense mechanism of the pancreatic cells by inducing the expression of the anti-
inflammatory genes. In addition, activation of NURP1 was found essential for the 
ability of tissues to tolerate lipopolysaccharide (LPS) treatment.(81) Interestingly, 
in THP-1 HCV infected cells, which showed a broad activation of inflammatory 
responses, NUPR1 was significantly downregulated.  
 
Interleukin 33, IL-33, an unconventional member of IL1 cytokine family, is 
mainly produced by structural and lining cells, so its expression was not changed 
in hepatocytes or Kupffer cells. Interestingly, IL-33 interacts with the transcription 
factor NF-kB and dampens its activity.(93) It is suggested that IL-33 prevents 
undesirable activation of inflammatory processes in endothelia despite constant 
exposure to NF-kB stimulators in the blood stream.(91-94) In addition, IL-33 
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serves as alarmin and has an important role in sensing damage in various 
infectious and inflammatory diseases.(91-94) IL-33 affects the various cell types, 
enhances the production of Th2 cytokines and Th2 cell mobilization.(91) IL‐33 can 
amplify polarization of alternatively activated macrophages to produce increased 
levels of CCL17 and CCL24 and induce proliferation and collagen production. 
Serum IL-33 levels were significantly upregulated in acute liver failure, suggesting 
it role as a potential marker of inflammation.(94)  
 
Collectively this data suggest an activation of transcriptional regulators that 
prohibit potentially dangerous and undesirable endothelial inflammation and 
provide anti-inflammatory state.  
 
The decreased expression of genes observed in the PRR-signaling pathways 
and activation of negative transcriptional regulators of the inflammatory response 
was further manifested by the downregulation of the cytokine–cytokine receptor 
interaction pathway. One of the most pronounced changes in this pathway was 
actually the significant absence of the expression of genes encoding 
proinflammatory cytokines including IL-1β, IL-6 or TNF-α. In contrast, chronic 
alcohol consumption was related with increase in RANTES production from normal 
endothelium, and ethanol induced a significant inflammatory response in rats 
LSEC.(136) Furthermore, attenuated inflammatory response in HCV exposed 
LSEC was in clear contrast to hepatoma and monocyte cell lines that expressed 
an increased expression of these genes. On the other hand, while conventional 
anti-inflammatory cytokine genes did not show major changes, a plethora of less 
known immunomodulatory genes were significantly upregulated. These include: 
 
ACP5 (acid phosphatase 5, tartrate resistant) gene encodes an iron containing 
glycoprotein (TRAP), which catalyzes the conversion of orthophosphoric 
monoester to alcohol and orthophosphate. Although originally discovered as a 
regulator of bone morphogenesis, TRAP role has been expanded to the regulation 
of innate immune responses and deficient ACP5 and TRAP function has been 
related with autoimmune disorders.(90, 137) Knock-out studies of ACP5 in mice 
model resulted in abnormal immunomodulatory cytokine responses; after LPS or 
S.aureus infection, TNF-α and IL-1β secretion was markedly increased in TRAP 
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deficient mice, which correlated with impaired microbicidal activity.(89) 
Interestingly, mutations in ACP5 genes were discovered in patients with immuno-
osseus dysplasia spondyloenchondrodysplasia (SPENCD) syndrome.(90) In these 
patients loss of TRAP protein results in a dramatic up-regulation of IFNα and type I 
interferon-stimulated genes.(90) More recently, TRAP was suggested as a 
macrophage-derived inflammation marker associated with cerebrovascular 
disease risk and with coronary vessel disease.(138, 139) Similarly as in LSEC, 
ACP5 was increased in THP-1 cells (4-fold). Thus, the marked upregulation of 
ACP5 expression in HCV infected LSEC might suggest a way of switching off 
inflammatory response as a way to prohibit a pathological inflammation that might 
damage the host.  
 
Furthermore, the abundance of transcripts coding for soluble inhibitors of 
inflammation suggest the more expanded role of LSEC in controlling inflammation 
within the liver. The most noticeable examples include: A2M inhibits biological 
effects of inflammatory cytokines and chemokines; C1QTNF1 has anti-
inflammatory and insulin sensing effects, NT5E increases extracellular levels of 
anti-inflammatory adenosine molecules; APOE modulates type I inflammatory 
responses; SERPING1 inhibits complement activation; HPX diminishes increase of 
TNF-α and IL6 in LPS stimulated macrophages.  
One of the significantly downregulated cellular pathways was TGF-β signaling. 
TGF-β is a central regulator in chronic liver disease contributing to all stages of 
disease progression from initial liver injury through inflammation and fibrosis to 
cirrhosis and hepatocellular carcinoma.(140, 141) The intracellular mechanism of 
TGFβ- signaling via kinase receptors and SMAD effectors is firmly 
established.(142, 143) TGF-β pathway was upregulated in previously published 
expression studies in hepatocytes, macrophages and chronic liver samples.(10, 
26, 61, 62) Furthermore, patients with chronic HCV infection have elevated plasma 
levels of TGF-β1 and increased expression of TGF-β1 in the liver, while the 
clearance of HCV infection with anti-viral treatment is associated with 
normalization of plasma TGF-β1 levels.(144) In contrast, we found significantly 
downregulated TGF-β2 with subsequent suppressed expression of the genes 
encoding for effector SMAD3, SMAD5 and SMURF and increased inhibitory 
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SMAD6 and SMAD7 transcripts. SMAD7 is a general antagonist of TGF-β family, 
while SMAD6 is specific for BMP signaling.(142, 143) Since, TGF-β is considered 
indispensable for angiogenesis, its activation in endothelial cells was extensively 
studied. It is proposed that the activation state of endothelial cells is regulated by 
TGF-β in two distinct ways. Whereas activation of the ALK1-Smad1/5 pathway 
induces the expression of proangiogenic genes leading to endothelial cell 
proliferation, migration and organization, the activation of the ALK5-Smad2/3 
pathway results in different signaling events associated with the expression of 
maturation-specific genes and inhibition of angiogenesis.(145) To our knowledge, 
this study is the first to report the simultaneous tuning down of the genes encoding 
for both signaling cascades integrated within the TGF-β pathway during HCV 
infection. 
  
Importantly, soluble inhibitors of TGF-β signaling pathways were significantly 
changed, suggesting that this might in vivo extent to surrounding cell types. These 
includes upregulation of thrombospondin- 2 and 3 (THBS2 and THBS3), both with 
a shown function as potent inhibitors of tumor growth and angiogenesis; 
upregulation of BMPER (BMP endothelial cell precursor-derived regulator), a 
secreted glycoprotein that binds directly and inhibits BMPs function; 
downregulation of latent transforming growth factor beta binding protein 1 and 2 
(LTBP1 and LTBP2) involved in immature TGF-β trafficking and activation in 
extracellular space. BMP signaling (part of the TGF-β signaling pathway) is 
essential for the inflammatory response of vascular endothelial cells. The BMPs 
(BMP2 and BMP4) might directly influence lesion progression through endothelial 
inflammation and cell differentiation.(95, 96) BMP4 was upregulated after HCV 
infection in LSEC, and its expression was significantly increased in mild and 
cirrhotic HCV+ livers, but not expressed in both hepatoma and THP-1 cells. This is 
supported by recent publication that has shown that LSEC are the major source of 
BMP4 in the liver and that BMP4 promotes HCV replication in hepatocytes.(129) In 
addition, in LSEC BMPER was significantly increased. BMPER is a key modulator 
in BMP signaling particularly in blood vessel formation.(96) It was shown that, lack 
of BMPER confers a proinflammatory endothelial phenotype with reduced eNOS 
levels and enhanced expression of adhesion molecules leading to increased 
leukocyte adhesion and extravasation in ex vivo and in vivo experiments.(96) Vice 
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versa, addition of BMPER exerts endothelium protective functions and 
antagonizes TNFα induced inflammation.  
 
There is a wealth of evidence that definitively establish TGF-β as a primary 
mediator in pathological fibrosis; increased expression of TGF-β1 correlates with 
ECM deposition, and delivery of exogenous TGF-β1 by various means to liver, 
lung or kidney tissues results in severe fibrosis in experimental animals.(145-148) 
There are now multiple reports that the therapeutic administration of TGF-β 
inhibitors ameliorates experimental fibrosis.(149-151) There are several reports 
that provide evidence that TGF-β1 positively regulates HCV RNA replication, and 
overexpression of TGF-β1 is an independent predictor for poor outcome of 
interferon and ribavirin therapy.(152-154) Our results might suggest that LSEC 
modulate TGF-β signaling pathway to control HCV replication in underlying 
hepatocytes and slow-down fibrogenesis. Functional studies are required to 
elucidate the mechanisms of these processes.  
 
Remarkably, semaphorin pathway emerged as a consistent finding in 
transcriptome analyses. The importance of plexins and semaphorins has been 
emphasized by their discovery in many organ systems including the nervous, 
epithelial, and immune systems as well as diverse cell processes including 
angiogenesis, embryogenesis and cancer.(119, 120) Studies of plexins and 
semaphorins have revealed that several members of these families are involved in 
a series of immune cell interactions, which ultimately influence the outcome of the 
immune response and substantially influence the level of inflammation by inducing 
proinflammatory cytokine production.(119, 120) Interestingly, semaphorins play the 
opposite roles in innate versus adaptive immune response, amplifying 
inflammation while dampening T-cell proliferation and activation.(119, 155, 156) 
Although “immune semaphorins” are crucial to various phases of the immune 
response, so far semaphorins have not been linked with HCV infection. While 
upregulation of downstream genes in both Kupffer cells and hepatocytes seems to 
activate the pathway, in LSEC seems that final outcome of semaphorins signaling 
could be inhibition of pathway on receptor or downstream levels (as presented in 
Figure 31). This might be explained by distinct roles of each cell type in HCV 
pathogenesis model: to amplify inflammatory response, KC activate semaphorin 
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pathways, while LSEC attenuate semaphorin signaling to prevent vascular 
inflammation. This data strongly indicate a pivotal role for these molecules in HCV 
pathogenesis. This is supported with finding of their increasing expression with the 
progression of the disease.  
 
Since LSEC can express MHC I and II class molecules and process antigens, 
have the potential of acting as antigen-presenting cells. This action has been well 
documented in vitro, but whether it occurs in vivo is still unclear. Although this 
experiment was not designed to answer the questions of T- and B-cell activation 
and antigen-presentation, it revealed changes in expression of genes that might be 
biologically relevant in regulating these processes. In LSEC, T-cell co-inhibitory 
ligands (HVEM, galectin) and soluble mediators (eNOS, HPX, IL33) were 
significantly upregulated. Meanwhile, prototypic co-stimulators of T-cell activation, 
CD80 and CD86, were not expressed, and negative co-stimulator of T-cell, PD-L1 
was downregulated. Recently it was reported that TLR-1, -2 and -6 stimulated 
LSEC induced T-cell proliferation as assessed by IFNγ production and proliferative 
activity, in the absence of significant upregulation of MHC class II, CD40, CD80 
and CD86.(128) It was shown that the expression of PD-L1 in LSEC and KC could 
inhibit the function of activated T cells via a PD-1 dependent and independent 
mechanism.(157, 158) Von Oppen et al described the mechanism of peripheral 
CD8+ tolerance in which antigen-specific retention of naive CD8+ T-cells in the 
liver represents the first step in the induction of CD8 T-cell tolerance toward 
circulating antigens that is executed by liver-resident scavenger LSECs.(152) Most 
of the studies examining LSEC anti-viral responses were performed using the 
murine LSEC in vitro models. Viral infection with murine cytomegalovirus caused 
functional maturation of antigen-presenting LSECs and was sufficient to promote 
antigen-specific differentiation into effector CD8+ T cells in the absence of 
dendritic cells and independent of CD80/86.(49) It is frequently suggested that 
uptake of viral particles by LSEC primes regulatory CD4+ T cells and impairs 
CD8+ T cells that finally fails to eradicate the virus from the liver.(51) This is 
generally supported of findings that HCV-specific CD8+ T cells in the liver 
frequently become dysfunctional and unable to secrete IFNγ or IL-2.(159) Notably, 
the studies describing potency of LSEC to induce HCV-specific T-cell tolerance or 
activation are required. 
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In general, hepatocytes are not easily accessible to immunocompetent 
leukocytes because LSECs may form an effective barrier between hepatocytes 
and the sinusoidal lumen. The trafficking of immune cells through the vascular 
endothelium is crucial in limiting tissue inflammation and unwanted damage.(160) 
Contradictory, we found upregulated both adhesion molecules permitting leukocyte 
extravasation, as well as endogenous anti-adhesion molecules. Liver biopsy 
staining analyses support this dual role of LSEC that simultaneously enable and 
limit cell-mediated inflammation. While neutrophil, macrophages and lymphocyte 
infiltration of liver is a hallmark of chronic hepatitis, the degree of which is usually 
mild and reflects in the progression that usually takes decades until cirrhosis and 
end stage disease is developed.  
 
Control of the cell trafficking is closely related with sinusoids structural integrity. 
While apoptotic death of HCV infected hepatocytes in clinically “silent” process, 
apoptosis of endothelial cells would cause disruption of their barrier function. As 
described in acute liver ischemia/reperfusion injury and acetaminophen induced 
liver necrosis, LSEC cell death is manifested with organ failure and fulminant 
course of the disease. In addition, the damage of LSEC is the first sign of graft 
rejection in liver transplant. In contrast to previous reports of HCV induced 
apoptosis in HUVEC, RNA-seq analysis revealed significant changes in anti-
apoptotic genes.(42) In addition, follow up apoptosis and cell death assays 
revealed no changes in the degree of apoptosis between HCV+ and control LSEC. 
Meanwhile, LPS significantly induced apoptosis. Similar observations were noticed 
in murine sepsis models, where LSEC apoptosis led to the organ dysfunction.(101)  
 
However, this is in contrast to in vivo observations of no local inflammation in 
the liver sinusoids resulting from portal blood endotoxaemia.(46) It was show that 
the proinflammatory cytokine IL-6, which is central to the development of 
inflammatory reactions in the liver, is produced by LSEC in response to low 
concentrations of endotoxin (100 pg/ml to 1 ng/ml) that was attenuated by KC, 
which locally release anti-inflammatory cytokines (such as IL-10) and down-
regulated liver inflammatory reactions to endotoxaemia.(161) Indeed, we have 
found a significant increase in anti-inflammatory cytokines in LPS exposed THP-1 
cells (IL10, IL4, IL11 IL13, ILRA) all able to provide inhibitory stimulus to LSEC. It 
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is important to note that our intention was to simulate overwhelming endotoxin 
exposure, so we used high LPS levels of 10µg/mL that would presumably 
overcome LSEC “intrinsic” insensitivity to low-level LPS exposure. Notably, we 
found a dramatic increase in inflammatory transcripts expression at early time 
point after LPS exposure, however this effect was attenuated by 48 hours time 
point. This correlated with significant upregulation of negative regulators of 
inflammatory response.  
 
The integrity of the liver sinusoidal endothelium is of highest relevance for the 
maintenance of liver physiology, and disruption of sinusoidal endothelial function 
have a prominent role in liver pathophysiology. LSEC dysfunction, with decreased 
intrahepatic NO production, has been considered as a relevant pathogenic factor 
in the progression of liver cirrhosis, while healthy sinusoidal endothelium is 
essential for liver regeneration.(162, 163) Early reports suggested that 
capillarization, loss of fenestration and formation of a basement membrane, 
precedes liver fibrosis that finally supports the activation of hepatic stellate 
cells.(164) Here we suggested new possible molecular mechanisms of these 
processes.  
 
However, a limitation to this study is that modeling LSEC function in vitro may 
not reflect their function in the liver milieu. LSEC immune phenotype may also be 
unavoidably modified upon isolation. In addition, this is a transcriptomic study, 
which provides changes only at mRNA level and functional studies at the protein 
level in future would help to confirm the changes reported here and transform them 
into a mechanistic overview. Time consuming and technologically challenging 
studies of LSEC isolated form HCV infected patients at different stages of disease 
are required. Notably, our study has already provided a number of possible new 
biomarkers and therapeutic targets for HCV infection. As Butler et al. showed, 
LSEC have multiple roles in maintaining tissue architecture through expression of 
soluble mediators.(165) This characteristic has already been exploited in the 
development of anti-tumor therapies targeting angiogenic factors.(166, 167)  The 
data presented here suggests that LSEC dictate the immune/inflammatory 
response to HCV infection. Given this influential role, it seems reasonable to look 
at LSEC as therapeutic targets to reinstitute normal immunity and resolve 
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inflammation. Due to the LSEC diverse functions, there are plentiful therapeutic 
strategies, ranging from exploitation of already present anti-inflammatory 
molecules to the blockade of leukocyte adhesion and antiangiogenic approaches, 
inhibition of LSEC proliferation and activation. Some of these have already been 
shown effective in human and experimental systems.(166, 167)  
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7. 
CONCLUSION 
 
To the best of my knowledge, this is the first comprehensive gene expression 
study on human LSEC in the course of HCV infection; therefore it has a very high 
significance for HCV research. Through the development of this project a series of 
novel results was obtained:  
 
1) Whole genome sequencing analysis revealed that LSEC expressed a wide 
repertoire of transcripts required for efficient immune response activation 
(including pathogen-recognition receptors, adaptor proteins, pro-/anti-
inflammatory cytokines, MHC molecules). 
2) Although HCV does not replicate in LSEC, a non-replicative HCV infection is 
sufficient to cause a broad and complex cellular transcriptional reprograming 
in wide range of gene functional categories. However, while HCV induced a 
significant upregulation of gene expression in hepatoma and macrophages 
in vitro cell culture systems, in LSEC a significant downregulation of gene 
expression was observed. 
3) Kinetics of gene expression might suggest early vs. late response to HCV 
infection, since the majority of gene changes were restricted to 8, 24 and 48 
hours time point rather than persisting across time points. This might be 
reflection of HCV potential for chronicity, where by shutting down LSEC 
«defense» properties, HCV delays cellular changes in order to prevent the 
activation of immune response.  
4) In HCV infected LSEC, the key innate immune response pathways were 
significantly downregulated (RIG-I and TLR-signaling pathways). This 
manifested by the decreased PRR transcripts with subsequent tuning down 
of the expression of the genes encoding for adaptor proteins, JAK-STAT, 
NF-κB and IRF signaling cascades, which resulted in the reduced 
expression of cytokine genes and reflected the deficiencies of innate 
immune response. The ability of LSEC to activate innate immune response 
was confirmed with LPS stimulation. 
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5) In control LPS stimulated cells, a dramatic increase in inflammatory 
transcripts expression at early time point after LPS exposure was observed. 
This effect was attenuated by 48 hours time point, which correlated with 
significant upregulation of negative regulators of inflammatory response.  
6) HCV induced activation and upregulation of transcriptional factors essential 
for the induction of anti-inflammatory state (such as MAFB, NUPR1, IL33, 
KLF15, CEBPD). Meanwhile, HCV downregulated transcriptional factors 
shown to promote inflammatory responses (ETV1, MITH, HDAC9, EGR3, 
IRF6). This data suggest an activation of transcriptional regulators that 
prohibit potentially dangerous and undesirable endothelial inflammation and 
provide anti-inflammatory state. 
7) In contrast to LPS, HCV did not induce expression of proinflammatory 
cytokines. Meanwhile, a plethora of immunomodulatory genes were 
significantly upregulated (such as ACP5, A2M, C1QTNF1, NT5E, 
SERPING1, BMPER) that might extend to surrounding cells and attenuate 
liver inflammation.  
8) While cultured human LSEC lack the prototypic co-stimulators of T cell 
activation CD80 and CD86 ligands for T cell activation, several T-cell co-
inhibitory ligands (TNFRSF14 and LGALS9) and soluble inhibitory mediators 
(NOS3, HPX, IL33) were significantly increased. 
9) The cell cycle pathway was significantly down-regulated in HCV exposed 
LSEC and the coordinated down-regulation of these genes appeared in all 
phases of cell cycle including G1 to S, G2 to M, and metaphase to anaphase 
transition.  
10) While LPS induced major changes in pro-apoptotic pathway, HCV induced 
only minor changes that implicated inhibition of apoptosis. Follow up 
apoptosis and cell death assays revealed no changes in the degree of 
apoptosis between HCV+ and control LSEC, while LPS significantly induced 
apoptosis. 
11) Total of 31 KEGG pathways was significantly enriched in HCV infected 
LSEC. Enriched were KEGG pathways related to cell scavenger functions 
(e.g. Fc gamma R-mediated phagocytosis, Cell adhesion molecules, Focal 
adhesion, Leukocyte transendothelial migration, Axon guidance), innate 
immune responses (RIG-I-like receptor signaling, cytokine-cytokine receptor 
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interaction, complement and coagulation cascades) and cancer development 
(Pathways in cancer, Apoptosis, p53 signaling, Wnt signaling). 
12) TGF-β signaling pathway was significantly downregulated in HCV infected 
LSEC. This reflected in the simultaneous tuning down of the TGF-β2 
expression with subsequent suppressed expression of the genes encoding 
for effector SMAD3, SMAD5 and SMURF and increased inhibitory SMAD6 
and SMAD7 transcripts. Meanwhile soluble inhibitors of TGF-β signaling 
pathways were significantly changed (BMPER, THBS2, THBS3), suggesting 
that this might in vivo extent to surrounding cell types. 
13) The only pathway enriched at all time points in LSEC (as well as in KC and 
Huh7.5 cells) was axon guidance, more specifically «immune semaphorins 
pathway». While upregulation of downstream genes in both Kupffer cells and 
hepatocytes seems to activate the pathway, in LSEC seems that final 
outcome of semaphorins signaling could be inhibition of pathway on receptor 
or downstream levels. 
14) The system biology approach helped to identify distinct gene expression 
profiles in HCV infected LSECs, KCs and hepatocytes, suggesting their 
different roles during HCV infection. Unlike RNA-seq analysis of 
macrophages that demonstrated a broad increase in IL1β and NFκB-
responsive proinflammatory cytokines and chemokines, HCV did not induce 
a marked increase in such inflammatory signals in both LSECs and Huh7.5 
cells. Analysis of genes within these pathways showed increased IL1β levels 
with increasing severity of liver disease and marked overlap in upregulated 
expression in macrophages exposed to HCV and liver specimens.  
15) In contrast, analysis of genes commonly expressed in LSECs exposed to 
HCV with HCV infected liver showed significant overlap of pathways 
associated with angiogenesis, adhesion, ECM-organization, and regulation 
of defense/immune responses among other.  
16) Selective dysfunction of KC and LSEC might be relevant by profoundly 
affecting the immune responses against HCV at the level of the infection 
site. 
17) RNA-sequencing approach proposed new potential biomarkers that need to 
further be investigated in clinical samples (such as BMPER, IL33, 
semaphorins). 
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Taken all together these results suggest that HCV triggers downregulation of 
cellular regulators of inflammation in LSEC, which is manifesting in disabled host-
cell innate immune response possibly spreading to surrounding cells by secretion 
of soluble immune mediators. Meanwhile, HCV activates a very potent 
inflammatory response in Kupffer cells that might be harmful and lead to tissue 
destruction without LSEC’s attenuating effects. Gene changes in hepatocytes 
imply a serving role for HCV production where virus can undisturbedly replicate in 
high titers, successfully inhibiting host-cell defense mechanism.    
 
 
Figure 39. Proposed model of HCV disease pathogenesis 
 
 
 
Finally, this research identified specific host genes and molecules that are part 
of the human antiviral response to HCV and possibly other viral infections. This 
might facilitate the development of more effective biomarkers, interventions 
against HCV infection and might aid in the development of novel strategies for the 
design of vaccines against HCV infection.  
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8. 
SAŽETAK / ABSTRACT in CROATIAN 
 
UVOD: Jetrene sinusoidalne endotelne stanice (LSEC) igraju ključnu ulogu u 
eliminaciji krvlju prenosivih virusa. LSEC čine 20% stanica jetre i predstavljaju 
jedinstvenu staničnu populaciju važnu za degradaciju bakterijskih produkata, 
prezentaciju antigena i indukciju «imunološke tolerancije». Iako su ti procesi od 
posebne važnosti u patogenezi HCV infekcije, uloga LSEC u kroničnom C 
hepatitisu je nepoznata.  
MATERIJALI I METODE: Cilj ove studije je primjenom metodologije sistemske 
biologije istražiti ulogu LSEC u HCV infekciji. Pol II selektirane RNK iz HCV, 
MOCK ili LPS stimuliranih LSEC bile su analizirane upotrebom RNK-sekvenciranja 
cijelog staničnog transkriptoma, s ciljem identificikacije diferencijalno eksprimiranih 
gena (DEG) i staničnih putova. Ekspresija gena je uspoređena s uzorcima jetre 
blage i uznapredove fibroze, hepatocitima i Kupfferovim stanicama. 
REZULTATI: LSEC ne podupiru HCV replikaciju, ali virus efikasno ulazi u stanicu. 
U LSEC identificirano je 754, 245 i 2543 DEG, 8, 24 i 48 sati nakon HCV 
ekspozicije. Dok je LPS stimulacija potaknula izuzetno snažnu aktivaciju upalnog 
odgovora, HCV je općenito doveo do utišavanja istog. Ključni putevi prirođene 
stanične imunosti bili su značajno utišani (RIG-I i TLR-signalni putovi), što se 
manifestiralo sniženom ekspresijom PRR gena, adaptorskih proteina, JAK-STAT, 
NF-κB i IRF signalnih kaskada, rezultirajući smanjenom ekspresijom citokina te 
odražavajući neučinkovitost imunološkog odgovora. Molekularni mehanizmi ovih 
procesa uključuju: aktivaciju transkripcijskih regulatora ključnih za indukciju 
protuupalnog odgovora (MAFB, NUPR1, IL33, KLF15, CEBPD) i inhibiciju onih koji 
promoviraju upalni odgovor (ETV1, MITH, HDAC9, EGR3, IRF6). Istovremeno 
solubilni imunomodulatori (ACP5, A2M, C1QTNF1, NT5E, SERPING1, BMPER) 
bili su pojačano eksprimirani, a potencijalno utišivaju upalni proces u jetri. Daljnja 
analiza je identificirala obogaćenim KEGG stanične putove povezane sa 
staničnom eliminacijskom funkcijom (Fc gamma R-fagocitozu, stanične adhezijske 
molekule, tkivna adhezija, transendotelna migracija leukocita, imuni semaforini), 
prirođenom i stečenom imunošću, karcinogenezom (putovi u razvoju karcinoma, 
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apoptoza, p53- i Wnt- stanični putovi). Za razliku od KC i hepatocita, TGF-β 
signalni put je bio značajno utišan u LSEC. Različiti profili ekspresije gena su 
identificirani u LSEC, KC i hepatocitima, sugerirajući njihovu različitu ulogu u 
patogenezi HCV infekcije. U makrofazima je identificirana pojačana ekspresija 
proupalnih citokina i kemokina, koja korelira sa stadijem jetrene bolesti. 
Istovremeno, usporedba LSEC i uzoraka HCV-om inficirane jetre pokazala je 
značajnu podudarnost u staničnim putovima povezanim s angiogenezom, 
adhezijom, organizacijom ekstracelularnog matriksa i regulacijom imunološkog 
odgovora.  
ZAKLJUČAK: Ovo je prva analiza ekspresije gena u LSEC koja je identificirala 
promjene u transkriptomu povezane s HCV infekcijom. Identificirani geni čine 
ključne kompontente staničnog imunološkog i upalnog odgovora i sugeriraju da 
LSEC utišavaju upalu u tijeku HCV infekcije.  
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9. 
ABSTRACT in ENGLISH 
 
PhD thesis: The role of liver sinusoidal endothelial cells in HCV infection 
PhD candidate: Neven Papic, MD 
Mentors: Assistant Professor Adriana Vince, MD, PhD, Professor Curt Hagedorn, 
MD, PhD 
Affiliations: University Hospital for infectious diseases Zagreb, Croatia. University 
of Utah, School of Medicine, Salt Lake City, Utah, USA.  
 
INTRODUCTION: Liver sinusoidal endothelial cells (LSEC) due to their 
extraordinary scavenger activity are playing a pivotal role in blood-borne virus 
clearance. LSEC account for the 20% of hepatic cells and are unique organ-
resident cell population with diverse functions, including degradation of bacterial 
by-products, antigen presentation and induction of tolerance. While these 
processes are particularly relevant to HCV infection, the role of LSEC in chronic 
hepatitis C is not defined. 
MATERIALS AND METHODS: Aim of this study was to apply systems biology 
approaches to evaluate the role of LSEC in HCV infection. Poly(A) RNAs from 
HCV, MOCK or LPS treated primary LSEC cultures were analyzed by RNA-
sequencing (Illumina) to identify differentially expressed genes (DEG) and 
biological pathways. Cell transcriptomes were compared to similar analysis with 
mild (no fibrosis) and severe (cirrhosis) hepatitis C livers, hepatoma and Kupffer 
cells. 
RESULTS: Following exposure LSEC internalized HCV, but failed to support HCV 
replication. LSEC overall displayed 754, 245 and 2543 DEG at 8, 24 and 48h after 
HCV exposure, respectively. While LPS stimulation triggered exceptionally potent 
activation, HCV in general induced a downregulation of inflammatory signals. The 
key innate immune response pathways were significantly downregulated (RIG-I 
and TLR-signaling pathways), which manifested by the diminished PRR transcripts 
expression with subsequent tuning down of the expression of the genes encoding 
for adaptor proteins, JAK-STAT, NF-κB and IRF signaling cascades resulting in the 
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reduced expression of cytokine genes and reflecting in the deficiencies of innate 
immune response. Molecular mechanisms of these processes involve: 
upregulation of transcriptional factors essential for the induction of anti-
inflammatory state (such as MAFB, NUPR1, IL33, KLF15, CEBPD) and 
downregulation of those shown to promote inflammatory responses (ETV1, MITH, 
HDAC9, EGR3, IRF6). Meanwhile, a plethora of immunomodulatory genes were 
significantly upregulated (ACP5, A2M, C1QTNF1, NT5E, SERPING1, BMPER) 
that might extend to surrounding cells and attenuate liver inflammation. Gene 
pathway analysis further highlighted enriched KEGG pathways related to cell 
scavenger functions (e.g. Fc gamma R-mediated phagocytosis, Cell adhesion 
molecules, Focal adhesion, Leukocyte transendothelial migration, Axon guidance), 
innate immune responses and cancer development (Pathways in cancer, 
Apoptosis, p53 signaling, Wnt signaling). In contrast to KC and hepatocytes, TGF-
β signaling pathway was significantly downregulated in HCV infected LSEC. The 
system biology approach helped to identify distinct gene expression profiles in 
HCV infected LSECs, KCs and hepatocytes. Macrophages demonstrated a broad 
increase in IL-1β and NFκB-responsive proinflammatory cytokines and 
chemokines, which correlated with increasing severity of liver disease. In contrast, 
analysis of genes commonly expressed in LSEC with HCV infected liver showed 
significant overlap of pathways associated with angiogenesis, adhesion, ECM-
organization, and regulation of defense/immune responses.  
CONCLUSION: This is the first comprehensive gene expression analysis of LSEC 
that provided insight into the broad portrait of genomic changes associated with 
HCV infection. These genes are critical components of host immune and 
inflammatory pathways and provide new evidence that LSEC downregulate 
inflammation during HCV infection.  
 !
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